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Abstract
Influenza is an infectious seasonal disease against which yearly vaccination is
recommended, especially for high risk populations. For a new vaccine, efficacy
is classically assessed in large phase III trials. Unfortunately, in the past years,
many trials have led to unexpected results. This work first aims to identify the
particularities of the context of influenza with regards to the vaccine development.
We confirm the link between post vaccination antibody response and vaccine
efficacy without being able to identify an absolute threshold of protection.
Combining simulations and analytical results, we then substantiate the limits of
the actual statistical regression models used to estimate vaccine efficacy. To
reach this goal, we had to develop a simulation framework for the generation of
phase III clinical trials time-to-infection data. Our methodology brings together
particularities of influenza and other infectious diseases as well as historical data.
Finally, we propose a new m...
Document type : Thèse (Dissertation)
Référence bibliographique
Benoît, Anne. Estimation of the efficacy of seasonal influenza vaccine : vaccine development,
statistical modelling and trial design.  Prom. : Legrand , Catherine
Estimation of the efficacy of seasonal
influenza vaccines:
Vaccine development, statistical modelling and trial design
A thesis submitted in partial fulfillment of the requirements for the degree of Doc-
teur en Sciences, Université catholique de Louvain, January 2015
ANNE BENOIT
Thesis committee:
Catherine Legrand, Supervisor (Université catholique de Louvain)
Pierre Devolder, President (Université catholique de Louvain)
Walthère Dewé (GSK Vaccines)
Philippe Lambert (University of Liège, Université catholique de Louvain)
Niko Speybroeck (Université catholique de Louvain)
Fabian Tibaldi (GSK Vaccines)

"Perfection is a theory. You cannot be a perfect
human being, perfect artist. But go through your
daily routine with hope you will be a little better
in all respects, and do something meaningful" –
Mikhail Baryshnikov

Acknowledgments
It is a pleasure to thank the many people who made this thesis possible.
I would like to express my special appreciation and thanks to my advisor, Catherine
Legrand. Catherine, thank your for your support and guidance throughout this project.
You have helped me to grow as a research scientist and were always there to encourage
me when I needed it.
I would like to thank the members of my committee, Walthère Dewé, Philippe Lambert
and Niko Speybroeck. Walthère, thank you for entrusting me with this project, for
your help and all the guidance you provided along the way. Thank you Philippe and
Niko. You brought diverse talents and perspectives to the table that improved my
project. I thank the jury members, Fabian Tibaldi and Pierre Devolder for their interest
and their suggestions during my private defense.
I am grateful to all the administrative staff of ISBA, Nancy Guillaume, Sophie Malali,
Nadja Pfeiffer, Maguy Hanon and Tatiana Regout. Beside the very much appreciated
practical support, you provide this institute with a sense of family that I am gonna
miss.
I would like to thank the people at GSK, for their help, suggestions and for providing
valuable data to help develop and illustrate this thesis.
Thank you Pierre Lebrun, Vincent Bremhost and Cédric Taverne for the precious
Bayesian help.
I would like to thank my colleagues whom I loved spending the past four years. First,
I thank Marco, the best colleague ever! I also thank Adrien, Alina, Diane, Federico,
Habiba, Jennifer and Sylvie who have made sharing an office such a tremendous expe-
rience. Thank you Alain, Anna, Aurélie, Benjamin, Catherine, Cédric, Céline, Fabian,
Maïlis, Mathieu, Michal, Nathalie, Nathan, Nicolas, Réjane, Vincent, who make ISBA
a warm and fun place to work.
Self-confidence has never been my strong point and beside the people I’ve already
thanked, I would like to express my gratitude to Bernadette Govaerts, Christian Ritter,
Bruno Boulanger, Astrid Jullion and Tom Jacobs for believing in me and helping me
believe in myself.
I have been blessed with a very loving and supportive family. Words cannot express
how grateful I am to my parents, my brother and my sister for their love and encour-
agement. You have always believed in me! Special thanks to Jean-Luc, my American
uncle, for the much appreciated English review. Thank you to my husband’s family
for their support and understanding.
The last person I want to thank is my husband. Olivier, thank you for being there, for
encouraging and supporting me and most of all, for reminding me there is a whole
world outside of my PhD.
Contents
1 Introduction 1
1.1 The context . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Motivation and objectives . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.4 The Influence 65 trial . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Assessing vaccine efficacy in influenza clinical trials 7
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.1.1 Vaccine efficacy . . . . . . . . . . . . . . . . . . . . . . . . 8
2.1.2 Design of VE trials . . . . . . . . . . . . . . . . . . . . . . . 9
2.1.3 Limitations of our work . . . . . . . . . . . . . . . . . . . . 10
2.2 Statistical models to analyse vaccine efficacy data . . . . . . . . . . . 11
2.2.1 RR as a ratio of risks: Cumulative incidence . . . . . . . . . . 11
2.2.2 RR as a ratio of incidence rates: Person-time approach . . . . 15
2.2.3 RR as the ratio of two forces of Infection: Hazards ratio . . . 16
2.2.4 Sources of heterogeneity . . . . . . . . . . . . . . . . . . . . 18
2.2.5 Presence of uncontrollable nuisance sources . . . . . . . . . . 25
2.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3 Correlate of protection for seasonal influenza 29
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.1.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . 32
3.1.2 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 33
3.1.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.2 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4 A simulation approach to understand failures from the past 45
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.2 Background and context . . . . . . . . . . . . . . . . . . . . . . . . 47
4.2.1 Simulation state-of-the-art and particularities of influenza . . 47
4.2.2 Simulation Framework . . . . . . . . . . . . . . . . . . . . . 51
4.3 Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.3.1 Original trial . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.3.2 Simulated trials . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5 Estimation of seasonal influenza vaccine efficacy 67
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2 Methods of analysis and issues . . . . . . . . . . . . . . . . . . . . . 68
5.2.1 Classical models . . . . . . . . . . . . . . . . . . . . . . . . 68
5.2.2 Issues with the classical models . . . . . . . . . . . . . . . . 69
5.3 Conditional versus marginal VE . . . . . . . . . . . . . . . . . . . . 70
5.3.1 Individual frailty . . . . . . . . . . . . . . . . . . . . . . . . 71
5.3.2 Number of daily contacts . . . . . . . . . . . . . . . . . . . . 73
5.3.3 Vaccine mechanism of protection . . . . . . . . . . . . . . . 74
5.4 Simulations study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
5.4.1 Simulation setting . . . . . . . . . . . . . . . . . . . . . . . 77
5.4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5.5 Additional results . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5.5.1 Univariate frailty . . . . . . . . . . . . . . . . . . . . . . . . 78
5.5.2 Cure model . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.5.3 Exponential model . . . . . . . . . . . . . . . . . . . . . . . 82
5.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
6 Accounting for strain heterogeneity in the estimation of VE 89
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
6.2 An introduction to Bayesian inference . . . . . . . . . . . . . . . . . 91
6.3 Analysis model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
6.4 Statistical intervals . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
6.5 Implementation of the methodology . . . . . . . . . . . . . . . . . . 97
6.5.1 Model estimation . . . . . . . . . . . . . . . . . . . . . . . 98
6.5.2 Intervals computation . . . . . . . . . . . . . . . . . . . . . 99
6.6 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
6.6.1 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
6.7 Reanalysis of trial Influence 65 . . . . . . . . . . . . . . . . . . . . 109
6.8 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.A Analytical derivations of the marginal posterior density for β1 . . . . 115
7 Conclusion 117
Bibliography 123

List of abbreviations
AR . . . . . . . . . . . . . . . Attack rate
CDC . . . . . . . . . . . . . Centers for Disease Control and Prevention
CI . . . . . . . . . . . . . . . . Confidence interval
CID . . . . . . . . . . . . . . Communicable infectious disease
COP . . . . . . . . . . . . . . Correlate of protection
CT . . . . . . . . . . . . . . . Clinical trial
EMEA . . . . . . . . . . . . European Medicines Evaluation Agency
EPV . . . . . . . . . . . . . . Events per variables
Exp. . . . . . . . . . . . . . . Experimental vaccine
FDA . . . . . . . . . . . . . . Food and Drug Administration
FN . . . . . . . . . . . . . . . False negative
FP . . . . . . . . . . . . . . . . False positive
GMT . . . . . . . . . . . . . Geometric mean titre
HI . . . . . . . . . . . . . . . . Antibodies against influenza Haemagglutinin
HR . . . . . . . . . . . . . . . Hazards ratio
IR . . . . . . . . . . . . . . . . Incidences ratio
OECD . . . . . . . . . . . . Organization for Economic Co-operation and Development
OR . . . . . . . . . . . . . . . Odds ratio
PCR . . . . . . . . . . . . . . Polymerase Chain Reaction
PH . . . . . . . . . . . . . . . Proportional hazards
PI . . . . . . . . . . . . . . . . Prediction interval
Ref. . . . . . . . . . . . . . . Reference vaccine
ROC . . . . . . . . . . . . . Receiver Operating Characteristic
RR . . . . . . . . . . . . . . . Risk ratio
SOP . . . . . . . . . . . . . . Surrogate of protection
TI . . . . . . . . . . . . . . . . Tolerance interval
TN . . . . . . . . . . . . . . . True negative
TP . . . . . . . . . . . . . . . True positive
VE . . . . . . . . . . . . . . . Vaccine efficacy
WHO . . . . . . . . . . . . . World Health Organization
Chapter1
Introduction
*
1.1 The context
Influenza virus infects from 5 to 10% of the population yearly (WHO 2012). Influenza
causes a benign if uncomfortable illness is healthy adults, but can lead to sever com-
plications, especially in fragile populations, including the elderly, young children and
people with concomitant conditions. Indeed, influenza seasonal epidemics cause an
estimated 250000 to 500000 deaths yearly (WHO 2012). Therefore, vaccination is
recommended by the World Health Organisation (WHO) especially in the high risk
populations. Unfortunately, ageing is associated with a decline in immune function
which results in reduced vaccine efficacy (VE) (Haq and McElhaney 2014). For this
reason, pharmaceutical companies are developing novel seasonal influenza vaccines
that offer better protection to this population.
To obtain marketing licensure, development of a new human medicinal product goes
through several clinical phases (ICH8 1998; WHO 2004). Phase I studies designed to
evaluate the safety of a product. Phase II studies are designed to provide preliminary
information about a a product to achieve a desired effect. In vaccine phase II studies,
the key vaccine effect is the induction of potentially useful immune responses, such
as the production of high levels of antibody against the targeted infection. Whether to
grant the marketing license is based on large phase III trials, called pivotal studies. In
a phase III trial, the efficacy and the safety of the product must be fully assessed. In
vaccine phase III trials, the efficacy outcome of interest is the occurrence (or not) of
the targeted disease, confirmed through laboratory analyses.
The clinical VE of a seasonal influenza vaccine is usually assessed in a large multi-
centered phase III trial. The objective of such a trial is to show that the experimental
vaccine reduces the risk of influenza as compared to a reference (placebo or a standard
vaccine) (Chan et al. 2003). Participants are vaccinated with either the experimental
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or the reference vaccine prior to the influenza annual season. During the surveillance
season, i.e. from November to April, influenza cases and times of onset are collected.
In subjects who present influenza symptoms, such as fever and cough, a nasopharyn-
geal swab is collected and analysed to confirm influenza infection.
1.2 Motivation and objectives
In the last decades, many trials have led to unexpected results, such as failure to
achieve any significant efficacy, or discordant results from one season to the next using
the same vaccine candidate and study design (Beran et al. 2009a,b). Although lack of
efficacy is unexpected, it could be the result of using an ineffective product. However,
discordant results are more perplexing (Dewé et al. 2013).
Our project has two main objectives: the first objective is to understand the particular-
ities of seasonal influenza and the context in which VE trials take place, by identifying
the various factors and sources of heterogeneity which may lead to achieving oppo-
site results with the same vaccine. The second objective is to use this information
to improve the design of future efficacy trials, to propose a new way of thinking the
design of future efficacy trials and to propose more appropriate statistical tools for the
analyses of such trials. This dissertation is meant as a detective work. First it identi-
fies the potential causes of failure of previous trials, then studies these hypotheses and
tests their validity. Specifically, we will investigate four hypotheses, each discussed
during a chapter of this document. This will lead us to the development of a specific
simulation methodology taking into account the characteristics of seasonal influenza
and also to a concrete new proposal to analyse large influenza VE trials based on pre-
dictive intervals. Throughout the thesis, we will illustrate our finding and apply our
proposed methodologies to a large influenza VE clinical trials which will be presented
at the end of this introductory chapter.
1.3 Outline
Chapter 2 of this thesis is an introduction about influenza and the development of a
seasonal vaccine. It includes a review of the literature regarding the state-of-the-art
in designing and analysing clinical trials (CT) data for assessing VE against seasonal
influenza. In this chapter, we identify and discuss various sources of difficulties and
potential causes of failure for VE CT.
Based on these findings, we explore in the next chapters four specific hypotheses as
why trials could fail to show significant VE, namely:
• Are the right products selected for phase III vaccine development? (Chapter 3)
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• Are the objective of VE trials too optimistic in an heterogeneous context? (Chap-
ter 4)
• Are the classical regression models adapted to the specificities of seasonal in-
fluenza? (Chapter 5)
• Are we addressing the right question in phase III VE trials? (Chapter 6)
In Chapter 3 we discuss the influenza vaccine development process and more particu-
larly the selection of the products to be tested in phase III. The capacity of a vaccine to
produce an immune response and more particularly the post-vaccination levels of IgG
antibody to haemagglutinin (HI titres) are used as a correlate of protection (COP) for
VE, i.e. an indicator of the person protection against the targeted virus. We want to
test whether this particular immune response is a good indicator of VE. To do so, we
did an a posteriori analysis of a pooling of four efficacy trials in which both HI titres
and disease occurrence data were collected for a proportion of the participants. We
faced difficulties due to the differences between the trial designs and populations and
the lack of exposure information. We concluded that while post vaccination HI titres
were linked to VE, they were not sufficient to predict disease occurrence.
When designing a new VE CT, the required sample size is computed to reach a given
power to detect a given target VE, while controlling for the type I error rate. In case
the real VE is actually lower than the target level, the real power of the trial will
actually be (much) smaller than expected, which will lead to an "under-powered" and
often inconclusive trial. Determining, a priori, an adequate target VE is therefore a
crucial step in designing a CT. This target VE is often defined for an expected number
of influenza cases and will therefore depend on the attack rate (AR). A first issue is
that the AR can vary from one season to the next and from region to region. An other
challenge is that influenza is a multi-strain virus (Green et al. 1982). Type A virus
sub-strains take the form of HxNx, for example H1N1 and H3N2. Type B viruses are
divided into two lineages: Yamagata and Victoria. Genetic mutations are common and
a constant monitoring of the changes in the circulating viruses is necessary (Hay et al.
2001). Typically, a seasonal influenza vaccine contains three strains, two A and one B,
identified by the WHO as the most likely to circulate in the subsequent season. When
the predictions of WHO are incorrect, a mismatch occurs. In Chapter 4, we propose to
formalize these potential sources of heterogeneity. Based on this model, we develop
a simulation algorithm which allows to study the impact of complex combinations
of protocol hypotheses on the power of the trial. As we will demonstrate, by re-
simulating various scenarios of a large failed phase III trial, such a tool can be very
helpful in the design of new VE CT.
Classically, VE is estimated through logistic, Poisson or Cox regression models (Hal-
loran et al. 1997). These models assume that the observations are independent and
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identically distributed, given the covariate(s) if any. The subject heterogeneity de-
scribed in the context of a VE trial in chapters 2 and 4 makes us question the validity
of such assumption and about its impact on the VE assessment. In Chapter 5, we
explore the adequacy of these classical regression models for estimating seasonal in-
fluenza VE. We investigate, first analytically then through a large simulation study, the
impact of omitting these sources of heterogeneity. Interestingly, we show that when
the data is highly censored, models omitting sources of heterogeneity can sometimes
give better estimates than more complex models.
In chapter 6, we question whether the confidence intervals (CI) around the global VE
estimates are informative enough from the public health perspective. We propose a
model taking into account VE heterogeneity between geographical regions and flu
seasons. Based on our model, we suggest the use of predictive intervals instead of
confidence intervals in order to better reflect information about future VE. We study
the properties of this new methodology via a large simulation study and apply it on
data from an existing large CT.
In the last chapter of the thesis, we summarize and discuss our findings.
1.4 The Influence 65 trial
Throughout this thesis a large VE trial will be used as an illustrative example and we
will apply our methodological work to this specific data set. Data from the Influence
65 trial were provided to u by GSK Biologicals. Results of this trial are published in
McElhaney et al. (2013).
The Influence 65 trial was a randomized, observer-blinded study of the relative effi-
cacy of an adjuvanted new trivalent vaccine versus the standard non-adjuvanted triva-
lent vaccine (McElhaney et al. 2013). The primary objective was to demonstrate the
superiority of the new vaccine over the standard vaccine in preventing laboratory con-
firmed cases of influenza A and B in elderly adults aged ≥65 years. The study in-
cluded 43695 subjects from 15 countries vaccinated during the 2008-2009 (year 1)
and 2009-2010 (year 2) seasons. Participants were scheduled to receive one vaccine
in each year, and remained in the same group in years 1 and 2. In both years, the
influenza A antigens included in the vaccines were H1N1 and H3N2 strains. In year
1, the influenza Yamagata lineage B strain was foreseen by the WHO and for year 2
the Victoria lineage B strain.
Additionally, in year 1, pre and post vaccination HI titers were measured in an im-
munogenicity subset including 2422 and 2408 subjects in the adjuvanted vaccine and
the standard vaccine groups, respectively.
In year 1, 274 and 310 subjects were infected in the new and standard vaccine groups
respectively. Mean VE of 12.11% (95% CI: −3.40 to 25.29) was estimated through
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a Cox regression model. Superiority of the adjuvanted could not established as the
lower limit of the 95% CI for relative efficacy did not meet the predefined superiority
criterion.
Unfortunately, the circulation of the pandemic influenza A H1N1 strain started during
year 1 in some countries and generalized to all countries in year 2. Because of the
large antigenic distance between the seasonal and the pandemic strains it was decided
to exclude the pandemic flu cases from the efficacy analyses. The generalized cir-
culation of the pandemic strain during year 2 resulted in low circulation of seasonal
strains, which led to negligible AR. As a result, VE computations for the second year
could not be performed.
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Chapter2
Assessing vaccine efficacy in
influenza clinical trials:
state-of-the-art, challenges and
difficulties
This chapter is mainly based on the paper "Assessing Vaccine Efficacy in Influenza
Clinical Trials: Challenges and Difficulties" By Dewé W., Benoit A and Legrand C
and published in Expert Review Pharmacoeconomics & Outcomes Research, 2013
Jul;6(4):403-11.
The efficacy assessment of an investigational influenza vaccine often requires conduct-
ing large and expensive clinical trials. Particularities of influenza make singular such
an evaluation and increase the complexity of the study designs and the analysis of the
efficacy endpoints. Among others, these specificities are low attack rate, seasonality,
multiplicity of the flu viruses, potential mutations, heterogeneity of the virus circula-
tion in different region of the world and prediction of the vaccine composition.
In this chapter, we give an overview of the state-of-the-art for designing and analysing
phase III vaccine efficacy trials data. We discuss different particularities of the sea-
sonal influenza context and how they may impact the design, the conduct and the
analysis of a vaccine efficacy trial and explains why it could fail whatever the true
level of vaccine efficacy.
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2.1 Introduction
Clinical efficacy of a new seasonal vaccine is studied in a large phase III randomized
multi-centered trial. As a starting point for this chapter, over 100 trials were reviewed
to analyse the state-of-the-art in VE phase III trials. This non-exhaustive list of trials
includes observational trials as well as randomized clinical trials.
This chapter is divided into four sections. After a short introduction to VE design-
ing, data structure and data analyses, the classical methods of analyses for VE trials
are reviewed, detailed and discussed. The next section includes a non-exhaustive list
of issues linked to the influenza context and how they affect the quality of the VE
assessment.
2.1.1 Vaccine efficacy
In VE trials the goal is to show that the experimental vaccine reduces the risk of the
infection compared to a reference. The reference can either be a placebo or a vaccine
already approved for the studied virus. VE is defined as one minus the relative risk
(RR) for the studied endpoint between the experimental and the comparator subjects
(2.1.1) (Halloran et al. 2010). It represents the prevented proportion of infections in
the subjects who received the experimental vaccine compared to those who received
the reference.
V E = 1−RR (2.1.1)
Vaccines affect a population in many ways (Halloran et al. 1997). Vaccine effect for
susceptibility refers to how protective vaccination is against infection. Vaccine effi-
cacy for progression is sometimes also assessed in clinical trials. It measures how the
progression of a disease is affected by the experimental vaccine. Important factors
include any effect on the length of illness, a reduction in complication rate or severity
of the infection. Indirect effects of vaccination are sometimes studied, although not
in phase III trials. Herd immunity (Fine 1993; John and Samuel 2000), for example,
refers to how a community is indirectly protected by the vaccination of some of its
members by reducing the circulation of the virus. Finally, effectiveness, which mea-
sures how well a treatment works in practice, as opposed to efficacy, which measures
how well it works in clinical trials, can be estimated based on surveillance data. Here,
only vaccine efficacy for susceptibility will be discussed as it is the primary endpoint
of phase III efficacy trials.
Success criteria for a trial can either be the non-inferiority or the superiority of the
tested vaccine relative to the comparator. Non-inferiority trials are intended to show
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that the effect of the new vaccine is not worse than that of an active control by more
than a small pre-specified margin while offering other advantages such as a better
safety profile. Superiority trials are intended to show a difference greater than a spec-
ified minimum bound. In superiority vaccine efficacy trials, success typically requires
showing efficacy greater than a pre-specified clinically meaningful threshold, substan-
tially greater than zero (Nauta 2010). The VE parameter is defined as one minus the
ratio of the risks between the two groups, RR. A (one-sided) hypothesis test can be
written equivalently in term of VE or RR (Dewé et al. 2013).
{
H0 : V E ≤ ν0
HA : V E > ν0
⇐⇒
{
H0 : RR ≥ 1−RR0
HA : RR < 1−RR0
(2.1.2)
where ν0 = (1 − RR0) is the clinically-relevant threshold of success. When the test
is performed at the α level of significance, efficacy is statistically demonstrated when
the lower limit of the two-sided (1−α)100% confidence interval of the estimated VE
is larger than ν0.
2.1.2 Design of VE trials
Phase III clinical trials often include large numbers of subjects. To achieve the recruit-
ing rate, especially for a seasonal disease, most efficacy trials are done across multiple
centres in multiple countries.
Usually, trials are run over a single season. However, in some cases, trials for influenza
vaccines which continue for two to four years have been found. Various randomiza-
tion schemes were found in the reviewed trials including more than one flu seasons.
Vaccine can be given based on a unique randomization list. In this case, the subjects
are allocated to a vaccine group at the beginning of the trial and keep the same vaccine
for all the studied seasons (Edwards et al. 1994). This design might be considered as
unethical as some subjects will never benefit from the vaccine. On the opposite, a
new randomization list can be generated at each new season. The vaccine received
can thus change every year. This design is more ethical but may create issues when
vaccine history is an important covariate. Finally, some studies are particularly inter-
ested in the vaccine effect in naive subjects. In this case, subject who have previously
been vaccinated are allocated to the vaccination group while naive participants are
randomized between vaccine and placebo group (Keitel et al. 1997). New subjects
are recruited every year and placebo subjects from the year before are added to the
vaccinated group. VE can be estimated overall or for each season.
Other types of trial designs have been proposed to collect information on virus ex-
posure. In a challenge trial, after vaccination, subjects are inoculated with the virus
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and isolated in a quarantine health unit (Clements et al. 1984). The apparition and
severity of the disease is closely monitored. VE estimated in this design is conditional
to the knowledge of exposure. However, such trials are not allowed anymore in the
context of influenza as the disease can cause severe complications. In past studies, the
population that could be included in a challenge trial trial also very restricted: they
could never be performed in the populations most at risk from influenza, the elderly
and young children. In household contacts studies, disease occurrence in the family
members of index cases are collected, allowing for partial information about disease
exposure(Longini et al. 1982; Esposito et al. 2003). In Chapter 3 the importance of
some knowledge about exposure will be discussed.
In the trials discussed here, the censoring mechanism is primarily administrative: sub-
jects who did not have the event by the end of the trial are considered as censored. The
cumulative incidence of influenza infection by the end of the season, i.e. the attack
rate (AR), is usually low resulting in highly censored data. This point will be of par-
ticular interest in Chapter 5. Withdrawal from the study or lost to follow up constitute
the second censoring mechanism. Both these types of censoring are usually consid-
ered as non-informative. A third mechanism of censoring, departure from the trial
due to a severe adverse event might be informative. Indeed, events such as hospital-
ization, pneumonia, heart attack or death might be related to an episode of influenza.
In a healthy adults population, they are rare and can be ignored while in elderly, the
occurrence of such events is often analysed separately (Gross et al. 1995; Rothberg
et al. 2008).
2.1.3 Limitations of our work
Due to the characteristics of influenza, there are limitations to the modifications we
can bring to the design of VE trials. The first limitation is ethical. While inoculating
the virus to all trial participants would insure that all of them have been exposed, such
a procedure is consider as non-ethical and not authorized by the health regulatory
authorities. Also, in populations where annual vaccination is recommended, such as
the elderly, the use of a placebo vaccine is not allowed and the reference vaccine is
then the standard of care. This particular topic will be discussed in Chapters 3 and 4.
A second limitation is economical and practical. Because seasonal influenza only
affects a small portion of the population, VE trials usually include many subjects (over
43000 for trial Influence 65, see section 1.4 in the previous chapter). Because of the
large trial sizes, collecting a lot of information about trial participants, or taking blood
samples in all of them is very costly and not feasible in practical.
A third limitation is linked to the vaccine effect duration. The impact of previous
vaccinations on actual vaccine efficacy is controversial. This topic will be discussed
in Section 2.2.4 of this chapter. As a result, alternating between different vaccines,
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such as in a cross-over design, is not feasible and parallel designs are preferred. We
do not rethink the two-arms randomized double-blind parallel design generally used
for phase III VE trials.
Finally, the motivation for our researches is the failure of several phase III VE trials.
We mainly concentrate our researches on this phase of development.
2.2 Statistical models to analyse vaccine effi-
cacy data
In this section we propose an overview of the statistical models classically used to
analyse VE data. The assumptions of those models as well as their applicability to the
specific case of seasonal influenza will be discussed and explored in Chapter 5.
The risks ratio between the experimental and the comparator vaccine groups, RR,
is ψ1ψ0 . Depending on the level of information collected about the occurrence of the
disease, ψ0 and ψ1 can be modelled differently. When only the status (infected or
not) of the participants at the end of the trial are known, ψ0 and ψ1 are respectively
the cumulative incidence in the reference and the comparator groups. If time-to-event
data are collected, ψ0 and ψ1 are defined as incidences or hazard rates.
2.2.1 RR as a ratio of risks: Cumulative incidence
Estimating the relative risk of infection based on the cumulative incidence requires
only information about the number of subjects and influenza cases in each group dur-
ing a fixed surveillance period. The cumulative incidence is calculated as the ratio
between the number of influenza cases occurring during the surveillance period and
the number of subjects in each group. VE is defined as one minus the cumulative
incidences ratio between the experimental and the comparator vaccines.
Non parametric approaches
In the early seventies, VE was computed from the observed attack rates ratio of the
experimental and comparator groups (Hobson et al. 1973). A 2 x 2 contingency table
was generated from the data. To assess the significativity of the result, a Pearson’s
chi-square test was done, with the null hypothesis being a relative efficacy of one.
This simple approach presents several drawbacks.
The first drawback of the chi-square test is that it only allows for the null hypothesis
of equal efficacy. Yet, evidence of vaccine efficacy often requires a relative risk sig-
nificantly greater than 1 between the tested vaccine and the comparator (Chan et al.
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2003). Confidence interval can be built based on the asymptotic normality of the log
of the ratio of two proportions (Chan et al. 2003). Koopman (1984) proposed a method
for approximating confidence intervals for the ratio of two binomial proportions based
on two independent binomially distributed random variables. The confidence limits,
built from the chi-square distribution quantiles, cannot be calculated directly from a
formula, but must be derived iteratively. The Koopman’s chi-square method has been
used in several influenza vaccine efficacy trials in the nineties and is implemented in
several statistical softwares (Belshe et al. 1998, 2000). More recently, the exploding
power of computers has made possible the return to exact methods. Exact confidence
intervals conditionally to the total number of infection cases are now commonly re-
ported in vaccine efficacy trials (Ohmit et al. 2006). An exact confidence interval is
constructed by inverting the critical region of Fisher’s exact test (Ewell 1996).
The second drawback of the chi-square test is that it does not take into account the
possible presence of nuisance factors. The Mantel-Haenszel method allows the calcu-
lation of a weighted statistics adjusted for the effect of a stratification factor (Landis
et al. 1998). It estimates the association between the vaccine group and the event
variables, adjusted for the effect of the stratification factor. A common vaccine effect
can be estimated across the confounder strata using a weighted mean of a measure of
association. This test has been used in a few trials for the last two decades (Kawai
et al. 2003).
The biggest weaknesses of these methods is that they only allow the stratification over
categorical variables and do not allow the estimation of the covariates effects.
Parametric approaches
The logistic regression models are the most commonly reported methods in the anal-
ysis of influenza VE data (Edwards et al. 1994). They rely on cumulative incidence
and as such do not take into account the time of exposure. The estimated odds ratio
(OR) is often interpreted as an estimate of the RR despite their differences. However,
when the outcome risk is small, such as for seasonal influenza, the difference between
the OR and the RR is negligible and they can be interpreted similarly (Zhang and
Kai 1998; Lachin 2011). Figure 2.1 shows the evolution of the OR in function of the
prevalence of the event in the comparator group, and for different values of the RR.
Estimated RR can be derived from the OR (Zhang and Kai 1998) from:
RR =
OR
(1−AR0) + (AR0 ×OR) (2.2.1)
where AR0 represents the probability of event in the comparator group.
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As the RR between the tested vaccine and the comparator is expected to be smaller
than 1 (reduction of the risk with the new vaccine), the bias implies underestimation of
RR, i.e. an overestimation of VE. This particular effect will be examined in Chapter
5.
The logistic regression model is a special case of the generalized linear models, in
which the the link function is the logit link, log( pi1−pi ), where pi is the proportion of
events (Lachin 2011). Estimation of the model parameters is done through maximum
likelihood methods (Agresti 1996).
Based on the following model,
logit(pi|X1 = x1, X = x) = β0 + β1x1 + β′x (2.2.2)
where β0 is the baseline risk parameter, X1 is the vaccine group factor, β1 the re-
gression parameter for the vaccine effect, X contains the values and β the regression
parameters, β2 to βq+1, for the other q covariates. VE is defined as 1 − OR1 =
1− expβ1.
The center effect can be included in different ways in this model (Localio et al. 2001).
A fixed-effect logistic regression includes the center as an additive factor. As such,
centres included in the trial represent themselves rather than a sample of centres from
the population of all centres. We consider the case of J centres with j = 1, ...J . The
fixed-effects logistic regression model is of the form:
logit(pij |X1 = x1, X = x, J = j) = β0,j + β1x1 + β′x (2.2.3)
where β0,j is the baseline risk in the jth center, j = 1, ...J .
In a conditional logistic regression, center effects are considered as nuisance effects
and not estimated. This method is only appropriate when there are many subjects
per center as those where no event are observed do not contribute to the likelihood.
A mixed effect logistic regression assumes that the centres included in the trial are a
random sample from the population of centres. An overall vaccine effect is estimated
as well as a random center-wise baseline risk.
logit(pij |X1 = x1, X = x, J = j) = β0 + β0,j + β1x1 + β′x (2.2.4)
where β0 is the mean baseline effect and β0,j are the random center effects assumed
to be normally distributed with mean 0 and variance σ2β0 . Interaction fixed or random
effects between centres and other covariates can be included in all models.
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Figure 2.1: Relationship between OR and probability of event in the reference group
for varying levels of RR. The shaded band represents the expected AR for seasonal
influenza.
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2.2.2 RR as a ratio of incidence rates: Person-time ap-
proach
The incidence rate (IR) is the risk of experiencing an infection during a given time
unit. As opposed to relying on cumulative incidences, counting the number of events
by time-unit allows for different exposure times among the subjects. In large studies
where the disease incidence is low, it is assumed that the number of events in the vac-
cine and control groups may be approximated by independent Poisson distributions.
Conditional on the total number of events, the number of events in the vaccinated
group follows a binomial distribution (Lachin 2011).
Non parametric approaches
Confidence intervals for a ratio of incidence rates can be built based on the asymptotic
normality of the logarithm of such a ratio (Ewell 1996). Modern computing power
allows for an exact test to be constructed conditionally on the number of events, even
for large studies (Hoberman et al. 2003). As already mentioned, the non model-based
method presents the major drawback of not allowing the adjustment for continuous
covariates or more than a few categorical factors.
Parametric approaches
The multiplicative Poisson regression model is also a special case of the generalized
linear models with the logarithm as the link function. The time of exposure, ti, is
included in the model as an offset (Bridges et al. 2000; Frome 1983).
log(µ|X1 = x1, X = x, T = t) = log(t) + β0 + β1x1 + β′x (2.2.5)
where µ is the rate of events, t is the time of exposure , β0 is the baseline event rate
for one unit of time, X1 is the vaccine group factor, β1 the regression parameter for
the vaccine effect and X and β are the variables and the regression parameters for the
other covariates, with β = (β2, ...βq+1). VE is defined as 1− IR1 = 1− expβ1.
The Poisson regression model allows for the inclusion of continuous and categorical
covariates. Incomplete observations from drop-out subjects can be included in the
model as long as the censoring is not informative. As parameterized, the risk of infec-
tion over time is assumed to be constant, conditionally on the covariates included in
the model.
As for the logistic regression model, the center effect can be included as a fixed or a
random effect into the Poisson regression model. Estimation methods include maxi-
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mum likelihood and restricted maximum likelihood for the models including random
effects.
2.2.3 RR as the ratio of two forces of Infection: Hazards
ratio
A third way to look at the data is to consider the time between the start of the observa-
tion period and the day of onset of the event. Subjects who have not experienced the
event at the end of the follow-up period are considered censored . Time-to-event data
are usually described in terms of survival and hazard functions.
We define T as the time between the beginning of the surveillance period and in-
fluenza infection onset. The censoring time, C, is the time between the start of the
surveillance period and censoring, either the last contact with the subject or the end of
the surveillance period in the case of administrative censoring. The observed time-to-
event Y is the minimum between T and C and the censoring indicator variable δ is set
to 1 when the subject was infected by influenza during the surveillance period, 0 else.
We define f(t) as the probability density function of the event time t and F (t) the
corresponding cumulative distribution function
F (t) = P (T ≤ t) =
∫ t
0
f(u)du (2.2.6)
The survival function, S(t) gives the probability that a subjects has not yet experienced
influenza infection at time t
S(t) = 1− F (t) = P (T > t) (2.2.7)
The hazard function, h(t) gives the instantaneous rate at which influenza infection
occurs for subjects still at risk:
h(t) = lim4t→0
P (t ≤ T < t+4t|T ≥ T
4t =
f(t)
S(t)
(2.2.8)
The cumulative hazard function,H(t), gives the accumulated risk of infection by time
t
H(t) =
∫ t
0
h(u)du (2.2.9)
The impact of the covariates is often modelled via this hazard function, like in the Cox
regression model (Cox 1972), one of the most popular model for time-to-event data.
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VE represents the reduction in the instantaneous hazard of infection in the experimen-
tal group compared to the reference group, the hazard ratio (HR).
Non parametric approaches
Time-to-event data can be analysed through non-parametric methods. In this case,
no assumptions are made on either the baseline or the covariate part of the hazard
function.
One possible non parametric way to estimate S(t) is the Kaplan-Meier curve(Treanor
et al. 2011). The log-rank test can be used to test for evidence of a vaccine effect.
Extensions of this test, using different weight repartitions over the timeline of events,
are possible. However, as with all non-model based methods reviewed in this section,
working with multiple categorical covariates is not possible. Beran estimator (Beran
1981) is a non-parametric asymptotic estimation of S(t) which makes the inclusion
of a continuous covariate possible via kernel functions. Non-parametric methodolo-
gies cannot be used either to explore (and adjust for) the effects of several variables.
Finally, no parameter to summarize the magnitude of the vaccine efficacy is available
with these methods.
Parametric approaches
Several modelling statistical techniques for modelling the relationship between time-
to-event and several explanatory variables have been developed. These techniques
includes parametric and semi-parametric methods. The parameters β are usually as-
sumed to be time-invariant, although extensions to estimate time-dependant coeffi-
cients have been proposed. One possible choice is to assume a time-constant multi-
plicative relationship between the underlying hazard function and the log-linear func-
tion of the covariates, leading to hazards proportionality (PH) over time.
h(t|X1 = x1, X = x) = h0(t) exp(β1x1 + β′x), i = 1, ..., n (2.2.10)
where h(t) is the hazard function, X1 is the vaccine group factor, β1 the regression
parameter for the vaccine effect and and X and β are the variables and the regression
parameters for the other covariates, with β = (β2, ...βq+1). VE is defined as 1 −
HR1 = 1− expβ1.
In the Cox regression (Cox 1972), a semi-parametric model, no assumptions are made
about the nature or shape of the hazard function. The baseline hazard is unspecified
and the regression coefficients are estimated by the method of the partial likelihood
(Machin et al. 2006).
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Fully parametric PH model have the same form as the Cox regression model but, in
addition, assume a particular distribution of the time-to-event (Figure 2.2). The ex-
ponential model corresponds to assuming that the survival times are exponentially
distributed leading to a constant baseline hazard. Weibull distribution of the survival
times coincides with a monotone baseline hazard. In the lognormal model and the
log-logistic model the baseline hazard has the value 0 at t = 0, increases to a maxi-
mum and then decreases as t becomes large. Completely parametric models are more
efficient than Cox regression if the underlying model is correct (Nardi and Schemper
2003). However, their assumptions seem rarely tenable, especially in the case of a
seasonal infection such as influenza.
In PH models, center effects can be included as strata, fixed effects or random effects
(corresponding to the shared frailty model) (O’Quigley and Stare 2002). The first
solution is only possible for categorical covariates but offers the advantage of not
assuming PH between strata. For fixed and random effects, PH is assumed between
the levels of the covariates.
The stratified model
h(t|X1 = x1, X = x, J = j) = h0(t, j) exp(β1x1 + β′x) (2.2.11)
where = h0(t, j) is the jth center baseline hazard, j = 1, ...J .
The fixed effect model
h(t|X1 = x1, X = x, J = j) = h0(t) exp(cj + β1x1 + β′x) (2.2.12)
where cj is the jth center effect, j = 1, ...J .
The shared frailty model
h(t|X1 = x1, X = x, J = j) = h0(t)uj exp(β1x1 + β′x) (2.2.13)
where uj is the random effect for the jth center, j = 1, ...J and the random variable
U has probability density fU , called the frailty distribution.
2.2.4 Sources of heterogeneity
Sources of heterogeneities are numerous in the context of influenza. The main ones
and their effects on VE are reviewed in this section. Figure 2.3 represents the sources
of heterogeneity as well as their interactions. In chapter 4, we develop a simulation
methodology fitted to this schema.
In red, we present the main components of a phase III VE CT: trial subjects are vac-
cinated either with the comparator or the experimental vaccine. During the viruses
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Figure 2.2: Hazard functions examples, h(t), for exponential, Weibull, lognormal and
log-logistic time-of-event distributions.
20 Chapter 2. Assessing vaccine efficacy in influenza clinical trials
circulation period, subjects from both vaccination groups may get infected and suffer
from clinical influenza.
The statistical analyses applied to trial data are presented in pink. VE is estimated
through logistic, Poisson or Cox regression models and decision about the efficacy
of the experimental vaccine is taken based on a confidence interval for this quantity.
Statistical analyses models have been presented in section 2.2 of this chapter and the
quality of their estimates of VE in the context of influenza will be assessed in Chapter
5.
Several sources of difficulties arise in this simple scheme and will be discussed in
the subsequent sections: mismatching between the vaccine and the circulating strains,
heterogeneity in the intensity of circulation and the infectiousness of the circulating
viruses and heterogeneity in the vaccine efficacy mechanisms. The impact of these
sources of heterogeneity on the estimation of VE will be assessed and discussed in
Chapter 5.
The green part of the schema summarizes the objective of a correlate of protection
study. Prior to phase III, the clinical development of a new vaccine is based on its
potential to induce an immunogenicity response. This response is evaluated through
a post vaccination blood sample analysis. The goal of a COP study is to study the
link between the post-vaccination immunogenicity response and the risk of infection
with the virus strain of interest. One source of heterogeneity in this process occurs at
the blood sample analysis phase: between laboratories and inter-run variances are two
potential sources of difficulties. We present a COP study for one strain of influenza
in Chapter 3. This study is based on a pooling of four efficacy trials and the problem
of between trials heterogeneity, due to laboratory differences for example, will be
illustrated and discussed.
External sources of heterogeneities are presented in blue. The main one is the subject
himself. This topic will be presented in section 2.2.4 and its impact on COP and
VE estimations will be discussed respectively in Chapters 3 and 5. Other possible
sources of heterogeneities are linked to the passage of time: first, we point out the
seasonality of influenza, which will be of particular interest in Chapter 5. Second,
between seasons and within a season, circulating strains of viruses tend to change,
due to mutations for example. Impact of this effect on the estimation of VE and
solutions to take them into account in the design and the analysis of VE trials will
be presented respectively in Chapters 4 and 6. Finally, the effect of the vaccine itself
might be impacted by the time elapsed since vaccination. For example, there is a delay
between vaccination time and protection time. Also, VE may slightly decrease with
and influenza season, an effect called "waning". We do not discuss these issues.
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Subject
Not everybody is equally affected by influenza. Individual characteristics, such as
age, preexisting conditions or behaviours influence the probability of infection, the
response to vaccination and the severity of illness (Figure 2.3).
Influenza infection begins with exposure of the upper respiratory tract to the virus.
The infected host responds almost immediately to exposure, including through the
immune system (WHO 2012). People who have weaker immune systems, such as
the elderly, sick people, or young children, may be quickly overwhelmed by the virus
(Weinstein et al. 2003).
Vaccine effects are also mediated by the immune system. Given the same vaccine,
young children and elderly subjects appear to have a weaker antibody production than
healthy adults, resulting in a weaker protection. Immunosenescence in the elderly has
been studied extensively (Sambhara and McElhaney 2009; McElhaney et al. 2006). It
has been suggested (Pawelec 1999) that young children might suffer from an similar
condition.
Influenza infection is conditional to exposure to the virus. Flu can spread only short
distances between people, by direct contact with contaminated secretions or when
the virus is sneezed or coughed up with droplets of nasal secretions or saliva carried
over short distances into the air (Barker et al. 2001). As a result, different behaviour
patterns lead to varying exposure levels. For example, the highest infection rates are
found in children from 5 to 9 years old, who are likely to be in close contact with other
sick children and in institutionalized elders. On the opposite, non-institutionalized el-
ders tend to spend more time at home and have fewer contacts with infected persons.
Finally, health workers or people in contact with children are at greater risk of ex-
posure. Whereas age is recorded in clinical trials, occupation and and number of
contacts are usually not. Also, different sub-populations (age categories) tend to be
investigated in different trials. As a result, direct comparison of different age groups is
not possible and inter trial comparisons are flawed due to multiple disparities between
trials. This specific point will be discussed in Chapter 3.
Virus
Heterogeneity also arises from virus heterogeneity (Figure 2.3). Several types and
sub-types of influenza virus coexist and continually evolve. Mutations (antigenic drift)
and combination between viruses (shift or exchange of a genomic segment) modify
the structure of the virus surface antigens (Green et al. 1982). Current vaccines con-
tain three strains (A/H1N1, A/H2N3 and B) recommended annually by WHO. The
selected strains are the most likely to circulate in the subsequent season. Due to the
high mutation rate of the virus, a particular vaccine formulation looses efficacy rapidly
and annual vaccination is recommended. (Carrat and Flahault 2007).
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The level of infectiousness and the disease severity vary from one influenza strain to
another. For example, type A viruses are the principal causes of larger epidemics while
the type B viruses are often limited to localized outbreaks (WHO 2012). The A strains
are also more prone to mutations than B strains. Because of the high mutation rate of
the virus, infection occurring at the beginning of the season might not be caused by the
exact same virus as later in the season. Also, the repartition of the circulating strains
differs by geographical regions (Figure 2.4). For those reasons, heterogeneity in VE
between country is likely and should be taken into account in analysing international
trials. This particular point will be discussed in Chapter 6.
Vaccine
How vaccines protect against influenza is not completely understood. Smith et al.
(1984) consider two mechanisms of protection, Type I (leaky) and Type II (all-or-
none). In the former, vaccination is assumed to reduce the instantaneous disease rate
in all vaccinees by a constant proportion. In the latter, vaccination is assumed to
provide a constant proportion of individuals with complete immunity.
The mechanism of vaccine protection has an impact on the choice of efficacy mea-
sures (Halloran et al. 1997). On one hand, with a leaky vaccine, everybody has the
same baseline risk of infection. Vaccination multiplicatively decreases the risk in all
vaccinated subjects. As the season advances, the level of exposure grows and as a
result, cumulative infections rates increase (Figure 2.5). So, assuming a leaky effect,
the most appropriate models should take into account the time of exposure, such as the
Poisson and Cox regression models. On the other hand, an all-or-none vaccine does
not confer the same protection to all individuals. While individuals are completely
protected, others do not get any benefit. As a result, as the season advances and expo-
sure increases, the susceptibility of the vaccinated group will decrease possibly all the
way down to zero, once all non protected subjects have been infected. In presence of
a all-or-none effect, models assuming PH are not appropriate (Figure 2.5).
Most likely, influenza vaccination results in a mixture of the two mechanisms, con-
ferring no protection, heterogeneous partial protection and full protection to varying
proportions of the subjects. Natural immuno-protection (due to previous exposure to a
similar virus for example) probably leads to a similar pattern of protection heterogene-
ity in the non-vaccinated subjects. Halloran et al. (1997) suggests the use of survival
models including a degenerated frailty with a point mass at 0 to account for vaccine
protection mechanisms. This model will be discussed in Chapter 5.
Vaccine effect could also decrease along the flu season. This effect is called "wan-
ing" and contradictory results exist on the topic: Declining levels of antibodies in the
months following vaccination have been reported (Belongia et al. 2014). A review
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Figure 2.4: Percentages of respiratory specimens that tested positive for influenza by
strain (pie charts) and by influenza transmission zones between January 23 and 29,
2011.
Figure 2.5: Proportion of individuals without disease by time since start of the surveil-
lance period under the leaky (left) and the all-or-none (right) mode of action. From
Halloran et al. (2010).
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papers by Skowronski et al. (2008) reports, on the contrary, no such effect. We will
see in Chapter 5 that time varying covariate effect may be difficult to detect as it can
be confounded with latent individual heterogeneity.
Context
Context variables also induce heterogeneity in the effectiveness of an influenza vac-
cine. Vaccination recommendations differ between countries. For example, in the
US, influenza vaccination is recommended for all persons aged 6 months and older
while in some European countries, such as in Belgium, only the elderly are recom-
mended to be immunized. As a result, vaccine coverage is higher in the US, resulting
in decreased virus circulation and indirect protection of the unvaccinated subjects.
The impact of vaccine history on the actual vaccination effect has been frequently
discussed in the influenza research community. Annual vaccination is recommended
in the populations at risk of complications. While it has been suggested that protection
after annual influenza vaccination would successively decrease (Hoskins et al. 1979),
a review study by Beyer et al. (1999) did not confirm such results. If vaccine history
affects present vaccine efficacy, difference in efficacy could be observed in countries
making different recommendation policies.
2.2.5 Presence of uncontrollable nuisance sources
Vaccine efficacy estimation is also difficult because of nuisance factors and unknown
information. Non-matching between vaccine and circulating strains, the lack of a
surrogate of protection, seasonality of the epidemic and low attack rates are factors
discussed in this section.
Non-matching between vaccine and circulating strains
As mentioned in section 2.2.4, WHO recommends vaccine strains based on predic-
tions that are not always correct and mismatching can occur between circulating and
vaccine strains. If the antigenic distance between them is large, the vaccine will likely
offer no protection to the vaccinee. Thus, the effectiveness of the annual influenza
vaccine varies from year to year due to changes in the circulating influenza strains.
Current measures of antigenic distance are based on ferret antisera hemagglutinin in-
hibition assays (Gupta et al. 2006). If the distance is too large, influenza case is consid-
ered as non-matching and, depending on the protocol, might not be taken into account
in the efficacy estimation. Pharmaceutical companies are currently developing novel
influenza vaccines that would protect against more virus strains, either by including
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more antigens in their vaccines or by proposing formulations that would confer cross-
protection. However, as we will see in Chapters 3 and 4, the development of such a
product is very challenging.
No surrogate of protection
Immunity to influenza infection is a multi-factorial phenomenon. Specific IgG an-
tibodies, cell-mediated immunity and local antibodies all seem to play a role in the
protection against influenza (Nauta 2010). Unfortunately, the exact role of each con-
tributor is not yet fully understood. The level of IgG antibody estimated by the
haemagglutination inhibition titer (HI) is the easiest to measure and is usually the
primary endpoint in immunogenicity trials. Seroconversion, seroprotection and mean
fold increase (pre to post vaccination) are generally accepted as indicators of VE. For
urgently needed vaccine (pandemic vaccine for example) and for annual registration,
such an information is sufficient for the product to be approved for licensure. How-
ever, recent vaccines designed to increase the antibody responses have failed to show
superior efficacy with respect to the standard of care in large phase III trials (McEl-
haney et al. 2013). This matter will be discussed in Chapter 3.
Seasonality
In temperate climates, influenza infections are characterized by seasonality. The dis-
ease is marked seasonal peaks, typically during the winter months (Lofgren et al.
2007). The risk of infection is thus time-dependent. Statistical methods can be af-
fected by this characteristic. This issue will be discussed in Chapters 4 and 5.
Low attack rates
VE clinical pivotal trials are characterized by large sample sizes (over 43000 subjects
for trial Influence 65 for example), to reach a targeted statistical power to detect the
outcome of interest. In the context of influenza, attack rates in the unvaccinated pop-
ulation may vary widely and is not easy to predict accurately. Also, for the high risk
population, the use of placebo may be considered as non-ethical, especially in the
countries where vaccine policies recommend vaccination for those groups. All sub-
jects in the study are therefore vaccinated either with the tested vaccine or an already
marketed comparative vaccine, resulting in even lower infection rates. As a result,
the observed attack rates can be low and the sample sizes required to gather enough
events, very large. Observations are thus numerous, but only a small fraction of them
are informative. So, to reach the desired sample size before the start of the influenza
season, subjects are often recruited from multiple study centers.
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In the case of very efficacious vaccines, it may be that no or very few infections oc-
cur in the experimental group. In this case, there is a (quasi)complete separation of
response and non-responses by the vaccine variable. Heinze and Schemper (2001,
2002) show that this may lead to estimation issues due to the monotony of the likeli-
hood function. However, this situation is very rare, especially in influenza infections,
since more characteristic of small samples (n<200).
2.3 Conclusion
In this chapter, we presented information about seasonal influenza epidemics and the
methodology to assess VE against this infection. We showed that influenza presented
many characteristics that render the design and analysis of CT challenging. In the
subsequent chapters, specific difficulties will be detailed and further explored. The
impact of the contradiction between the heterogeneity of the seasonal influenza con-
text and the quite simple models used to analyse influenza VE trial will be studied in
Chapter 5. In chapter 6, we present a new methodology that accounts for some sources
of heterogeneity in the design, the analysis and the decision-making stages of a phase
III VE trial.
Summary of Chapter 2
• Influenza is a respiratory disease due to a viral infection against which vacci-
nation against influenza is recommended, especially for high risk populations
(elderly, children, etc.)
• VE is studied in large multi-centric international phase III trials and data are
usually analysed through logistic, Poisson or Cox regression models
• The context of seasonal influenza is heterogeneous and this heterogeneity may
be the cause of past failed trials
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Chapter3
Correlate of protection for
seasonal influenza
This chapter is based on the paper "Haemagglutination inhibition antibody titres as
a correlated of protection against seasonal A/H3N2 influenza infection" by Benoit et
al., and submitted to Open Forum Infectious Diseases
New influenza vaccines are classically developed based on their capacity to induce
an immunogenicity response. However, recent trials failures have emphased the lack
of evidence relating serum hemagglutinin-inhibition antibody levels to the risk of in-
fluenza disease.
In this chapter, we present a a correlates of protection analysis based on pooled
data from four randomized trials. We develop a logistic model to evaluate the titre
of A/H3N2 HI antibodies as a correlate of the occurrence of A/H3N2 disease. We
then build a receiver operating characteristic curve to identify a potential cut-off titre
between protection and no protection.
We confirm that there is a relationship between the occurrence of A/H3N2 disease and
HI antibody responses. Including age and epidemic intensity as covariates, a four-fold
increase in titre is associated with a two-fold decrease in the risk of A/H3N2 disease.
We find that an universal threshold of protection does not seem realistic since the pro-
tection level depends upon other factors, such as subjects characteristics and level of
exposure.
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3.1 Introduction
The HI titres estimating IgG antibody levels are traditionally used as markers of effi-
cacy in the earlier phases of influenza vaccine development. Seroconversion and mean
fold increase in HI titres(pre vs. post vaccination) are generally accepted as predic-
tive of vaccine efficacy. HI titres are considered a correlate of protection (COP), but
the mechanism of protection is not fully captured by this measure and the predictive
power of HI titres has not be proven in clinical trials (Qin et al. 2007). However, phar-
maceutical companies strongly rely on this measure in order to develop their products.
Every season, virus strains selected to be included in the annual vaccine may change,
making it impossible to perform a study to demonstrate the efficacy of the new vaccine
in the following season. Therefore, each year, vaccine are licensed based on immuno-
genicity measures that assume post vaccine HI titres above a defined threshold will
be sufficient to prevent influenza. Criteria recognized by the health European and US
regulatory authorities are presented in table 3.1.
EMA (Europe) FDA (US)
One criterion out of the 3 Both criteria
Point estimates Lower limit of the 95% CI
18-60y ≥60y 18-65y ≥65y
Seroconversion factor a >2.5 >2 NA NA
Seroconversion rate b >40% >30% >40% >30%
Seroprotection rate c >70% >60% >70% >60%
Table 3.1: FDA and EMA criteria for a successful phase II trial. a Geometric mean
titre increase ratio. b percentages of subjects with at least a factor 4 between pre and
post vaccination HI titres. c percentages of subjects with HI≥40.
Assuming a relationship between HI titres and VE, pharmaceutical companies are
attempting to develop new generations of flu vaccine or to extend licensures, based
on the sole immune responses. Recently however, the superiority of a new vaccine
candidate over a non-adjuvanted vaccine based on higher HI responses did not result
in superior vaccine efficacy in the large phase III trial influence 65 (McElhaney et al.
2013). As a result, further investigation is needed to determine whether HI responses
are a reliable endpoint to optimize the formulation of new vaccines and also to market
vaccines whenever performing a VE study is not possible.
Ideally, COP should be studied in a well-designed challenge trial as follow: first sub-
jects are vaccinated either with the experimental vaccine or the reference vaccine;
seconds, 21 days later, their immunogenicity response is measured through a blood
sample; third, they are inoculated with the virus strain(s) of interest and fourth they
are observed to determine the occurrence of the disease. However, such studies are
believed to be unethical and no longer approved. Therefore, COP are studied as an ex-
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ploratory endpoint of phase III trials: immunogenicity analyses are performed based
on the fraction of the study participants on whom both pre and post vaccination HI
titres are measured as well as the primary efficacy endpoint.
The main issue with COP as an exploratory endpoint of efficacy trials is that little
information is collected on the study participants. Influenza infection is conditional
on exposure to the virus. Contrarily to a challenge trial, efficacy trials provide no
information about the level of exposure of a subject. We know that infected subjects
were exposed to influenza. However, non-infected subjects are a mixed between two
populations: exposed subjects protected by the vaccine and non-exposed subjects who
were either protected or not.
Qin et al. (2007) provide a framework to assess correlates in vaccine trials. In their
classification, while a COP should be statistically correlated with the endpoint of inter-
est, a surrogate of protection (SOP) has a predictive power for the endpoint of interest
and is independent of the setting. Thus, to validate any correlate as a predictor of effi-
cacy it would be desirable to pool databases of different studies conducted in different
settings (Gilbert et al. 2008). The downside of pooling data from several efficacy tri-
als ran in different sub-populations and flu seasons, with different vaccines, is that it
leads to interpretation difficulties since an observed effect could be attributed either to
a covariate of interest or to inter-trial differences.
Furthermore, pharmaceutical companies would like to identify a threshold of protec-
tion titre above which a person would be considered as protected. An HI antibody
threshold of 1:40 is generally recognized as corresponding to a 50% reduction in the
risk of influenza, based on a challenge study in adults conducted by Hobson et al.
(1972). However, there is no consensus on the definition of "protection" with some
studies defining protection as a pre-defined risk reduction (usually 50%) and some
studies defining protection as the titre level providing the best separation between in-
fluenza cases and non cases (Dunning 2006). To date, there is little agreement on
what represents "protection" or any cut-off antibody titre between protection and non-
protection based on contemporary data from influenza vaccine trials.
Here we describe a COP analysis of pooled data from four randomized trials of sea-
sonal influenza including 7730 subjects. Our analysis is focussed on strain A/H3N2.
We model the data through a logistic regression model. To take into account the ex-
posure to the virus, we include season strength as a covariate. Based on our model
we build a receiving operating characteristics (ROC) curve in order to assess whether
post vaccination titres are associated with the prevention of the next influenza episode
(Zweig and Campbell 1993; Zou et al. 2007). We attempt to derive a post vaccina-
tion HI titres threshold between protected and non-protected subjects. We discuss our
results and provide recommendation for running future COP trials.
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3.1.1 Materials and Methods
The analysis was based on four phase III trials, two in subjects aged 18-64 years,
one in subjects aged 18-49 years, and one in subjects aged ≥ 65 years. In each ef-
ficacy study, immunogenicity assessments were performed on a randomly assigned
sub-cohort, and our analysis was performed on the per-protocol sub-cohort (including
subjects who met eligibility criteria, complied with the protocol, received any dose of
either vaccine, and for whom data were available):
1. Beran et al. (2009a) performed a randomized, double-blind, placebo-controlled
study of the efficacy of trivalent vaccine (TIV) against culture-confirmed in-
fluenza in healthy adults aged 18-64 years. A total of 4137 and 2066 subjects
received TIV or placebo, respectively, during the 2005-2006 season in the Czech
Republic. Our analysis included 632 and 315 subjects in the TIV and placebo
groups, respectively.
2. Beran et al. (2009b) performed a randomized, double-blind, placebo-controlled
study of the efficacy of TIV against culture-confirmed influenza in healthy adults
aged 18 to 64 years. A total of 5103 and 2549 subjects received TIV or placebo,
respectively, during the 2006-2007 influenza season in Czech Republic and Fin-
land. Our analysis included 291 and 148 subjects in the TIV and placebo groups,
respectively.
3. Jackson et al. (2010) performed a randomized, double-blind, placebo-controlled
efficacy study of TIV against culture-confirmed influenza in healthy adults aged
18-49 years. In this study, a total of 3783 and 3828 subjects received TIV or
placebo, respectively, during the 2005-2006 and 2006-2007 influenza seasons
in the US. Our analysis included 1298 and 216 subjects in the TIV and placebo
groups, respectively.
4. The Influence 65 trial (McElhaney et al. 2013) was a randomized, observer-
blinded study of the relative efficacy of an adjuvanted vaccine (AS03-TIV) ver-
sus TIV against PCR-confirmed influenza in healthy adults aged 65 and over.
The study included 43695 subjects from 15 countries who received AS03-TIV
or TIV during the 2008-2009 and 2009-2010 seasons. The immunogenicity
subset included 2422 and 2408 subjects in the AS03-TIV and TIV groups, re-
spectively, and this analysis included immunogenicity data from the 2008-2009
season.
Despite some specificities, the four trials followed the same general protocol. During
the study periods, subjects were monitored for influenza-like illness (ILI) by active
surveillance (telephone contact/study center visit/home visits by study personnel), and
by passive surveillance whereby subjects notified the study center if they experienced
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ILI symptoms. Nasal and throat swabs were obtained from subjects reporting ILI.
Laboratory identification of influenza viruses and case definitions in each study have
been previously described (Beran et al. 2009b,a; Jackson et al. 2010; McElhaney et al.
2013). In all studies, blood samples were taken before vaccination and 21 days after
vaccination to assess the level of serum antibodies in the immunogenicity sub-cohorts
subjects.
3.1.2 Statistical analysis
Descriptive analysis and modelling were performed on the four randomized trials. In
the descriptive analysis, the distribution of the following variables was characterized:
gender, age, seasonal influenza vaccination history within previous 2 years, A/H3N2
infection status by the end of the study season, pre- (Day 0) and post-vaccination
(Day 21) HI antibody titres against A/H3N2, pre-vaccination A/H3N2 seroprotection
status (HI titre ≥1:40), vaccine received (AS03-TIV or TIV), and season strength
("strong season" or "low/moderate season"). In Beran et al. (2009b,a) and in Jack-
son et al. (2010), the season strength was based on the WHO influenza surveillance
FluNet (Flahault et al. 1998) database and by evaluating the magnitude of the epi-
demics in the corresponding countries at the time the studies were conducted. In
the Influence 65 trial (McElhaney et al. 2013), season strength was based on national
surveillance data and attack rates in the study, as assessed by the Adjudication Steering
Committee for the influenza peak season , which included influenza research experts
independent of study sponsor. For continuous variables, the number of observations,
mean, standard deviation, and minimum and maximum values were computed. For
HI antibody titres, GMTs and their coefficient of variation were also calculated after a
log10 transformation. Frequency statistics, including counts and proportions were ob-
tained for the categorical variables. A preliminary graphical analysis was performed
to assess each covariate versus A/H3N2 attack rates. The proportion of subjects with
laboratory-confirmed A/H3N2 influenza was calculated for each dilution factor of the
post-vaccination HI antibody response against A/H3N2.
In the modelling part of the analysis, a logistic regression model was used to assess
the effect of exploratory variables on A/H3N2 disease occurrence. The following
covariates were considered: pre-vaccination immunity state (titre greater or equal to
1:40 defined as "protected"), Day 21 post-vaccination A/H3N2 log 10 titres, gender,
history of vaccination (vaccination 1 and 2 years before study start), age (Influence 65
trial≥65 years versus other trials <65 years), and season strength. A manual stepwise
variable selection was performed based on the Bayesian information criterion (BIC)
to select the best comb. ination of covariates to describe the disease occurrence. The
Akaike Information Criterion and Bayesian Information Criterion are both penalized-
likelihood criteria for model selection (Burnham and Anderson 2004). The BIC tends
34 Chapter 3. Correlate of protection for seasonal influenza
to select more parsimonious models compared to the AIC, which renders it preferable
in the specific context of COP.
A receiver operating characteristic (ROC) curve was derived, presenting the sensitivity
against one minus the specificity at various A/H3N2 HI antibody titre cut-off values
(see note 3.1.2). The Youden index (Youden 1950) was used to identify the lowest titre
at which the sum of the specificity and sensitivity was maximum. The Youden index
can be interpreted as a cut-off titre between protection and no protection: sensitivity
was defined as the proportion of subjects with confirmed A/H3N2 influenza and post-
vaccination titres below the cut-off value; specificity was defined as the proportion of
subjects in whom A/H3N2 was not confirmed and whom had post-vaccination titres
equal to or greater than the cut-off value. Because the non-cases included both pro-
tected subjects and not sufficiently exposed/non-protected subjects, we also derived a
cut-off post-vaccination titre value giving more weight to the cases detected, which we
defined as the HI antibody titre cut-off values for the detection of A/H3N2 influenza
with 90% sensitivity.
Note on the building of a ROC curve
The table below summarizes the possible outcomes of a test for detecting an event
of interest by crossing the true disease status (infected or not, column-wise) with the
test outcome (below or over the threshold of protection defined based on the logistic
regression model, row-wise). True positive occurs when the post-vaccination HI titre
is below the threshold of protection for a subject infected during the influenza season,
true negative when the post vaccination titre is over the threshold for a non-infected
subject.
Diagnosis based on Reality
the threshold of protection Not infected (I-) Infected (I+)
Not protected (< threshold) False positive (FP) True positive (TP)
Protected (≥ threshold) True negative (TN) False negative (FN)
Two types of errors can occur. First, false positive happens when a subject with a
post vaccination HI titre below the threshold, considered as not protected, did not get
infected by the end of the season. Second, false negative occurs in the opposite situ-
ation: post vaccination titre over the threshold of protection, considered as protected,
for a subject who got infected.
Specificity and selectivity are two popular indicators or the validity of a test for de-
tecting correct diagnosis. They are the probabilities of making a correct diagnosis
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among the infected subjects (I+) and the non-infected subjects (I-). In a ROC curve,
the following quantities are presented for varying levels of threshold of protection.
True Positive Fraction = Sensitivity =
TP
I+
(3.1.1)
and
False Positive Fraction = 1-Specificity = 1− TN
I− (3.1.2)
3.1.3 Results
An overview of subjects included in the analysis is shown in figure 3.1. Since the
elderly did not receive a placebo vaccine, as opposed to the young adults, there is less
data available for this population at low post-vaccination HI titres. The demographic
characteristics and geometric mean titres (GMTs) for subjects included in the analy-
sis by trial are shown in table 3.2. Pre- and post-vaccination GMTs in subjects who
received TIV or AS03-TIV were 10.5-17.4 and 131.7-285.6, respectively, and in sub-
jects who received placebo were 13.1-15.4 and 13.3-15.8, respectively. At baseline,
5405 (71.1%) subjects had an antibody titre against A/H3N2 that was <1:40 and 2309
(29.9%) had a titre that was above 1:40. Sixteen subjects did not have pre-vaccination
titre data available. The A/H3N2 infection rates by age and season strength are
shown in table 3.3. The frequency of A/H3N2 cases and post-vaccination HI an-
tibody titres against A/H3N2 are shown in figure 3.2. Among 1098/7730 (14.2%)
subjects with post-vaccination HI titres below 1:40, 24/1098 (2.2%) subjects had con-
firmed A/H3N2 illness; among 6632/7730 (85.8%) subjects with post-vaccination
titres above 1:40, 50/6632 (0.75%) had confirmed A/H3N2 illness.
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Age / trial Epidemic intensity Subjects A/H3N2 cases Infection rate
≥ 65 Low or moderate 2939 20 0.68
high 1891 40 2.12
< 65 Low or moderate 1873 4 0.21
high 1027 10 0.97
Table 3.3: A/H3N2 infection rates by age and epidemic intensity in subjects pooled
from four VE trials (immunogenicity sub-cohorts
Parameter 95% CI on
estimate p-value Odds ratio the odds ratio
Baseline risk -3.92 <0.0001
Post-vaccination log-titre -1.20 <0.0001 0.33 0.23, 0.46
Epidemic intensity 1.24 <0.0001 3.44 2.10, 5.64
Age/trial 1.24 0.0001 3.45 1.89, 6.32
Table 3.4: Logistic regression parameter estimates and odds ratios for the selected
model
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The selected model includes three covariates: post vaccination log-titres, age cate-
gory/trial and season strength. Table 3.4 shows the parameter estimates for the se-
lected model. The odds ratio for A/H3N2 infection in high versus moderate/low sea-
son was 3.4 (95% CI: 2.1, 5.6). The odds ratio of A/H3N2 infection in subjects aged
≥ 65 years versus <65 years was 3.03 (95% CI: 1.9, 6.3). In our model, a four-fold
increase in HI titre was associated with a 49.0% decrease in the risk of infection. Con-
sistency of the HI response across the HI range was an assumption of the statistical
model, which appeared acceptable based on the cases and HI titres observed (fig. 3.3).
The area under the curve for the ROC including age and season strength as covariates
was estimated at 0.77 (Figure 3.4). It is significantly different from 0.5 (p<0.0001).
The Youden index HI antibody titre cut-offs in subjects aged <65 years were 1:5 in
a low/moderate season and 1:40 in a high season; the cut-offs in subjects aged ≥65
years were 1:40 in a low/moderate season and 1:640 in a high season. The 90% sensi-
tivity HI antibody titre cut-offs in subjects aged <65 years were 1:28 in a low/moderate
season and 1:453 in a high season; the cut-offs in subjects aged≥65 years were 1:453
in a low/moderate season and 1:5120 in a high season.
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Figure 3.3: Estimated risk, point-wise 95% CI and observed proportions of clinical
infections over post vaccination HI log10 titres, by age/trial and season strength. Note:
the data point size represents the number of subjects for the post vaccination level of
HI titre.
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Figure 3.4: ROC curve for the selected model, including post-vaccination HI titres
(log scale), subjects age category and season strength as covariates. The area under
the curve is 0.7713 and is significantly different from 0.5 (p<0.0001)
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3.2 Discussion
In our COP analysis of four randomized trials, two in adults aged 18-64 years, one in
adults aged 18-49 years and one in adults aged≥ 65 years, age influenced the baseline
risk of A/H3N2 infection with an odds ratio of 3.4 for subjects aged≥ 65 years versus
<65 years. Including age and season strength as covariates, a four-fold increase in
titre was associated with a two-fold decrease in the risk of A/H3N2 infection, with
a similar difference in risk observed when including only age as a covariate. While
age did not appear to affect the serological response to vaccination, older subjects
appeared to have a greater risk of infection at similar titres compared with younger
subjects. The Youden index cut-off values in a high season were 1:28 and 1:453 in
subjects <65 years and ≥65 years, respectively.
Some factors that are confounded with differences between the trials: the nature of the
comparison (placebo or active reference), influenza case definitions, laboratory meth-
ods for viral detection (culture or PCR), HI measurements, the age of participants
(18-64 years, 18-49 years, ≥65 years), and the fact that the studies were conducted
in different countries and seasons. In addition, cell-mediated immunity may impact
protection against influenza, and the influence of mechanisms other than humoral im-
munity (based on HI titres), was not accounted for in our analysis. We believe that the
most important differences among the trials were age, the endpoint that considered all
cases of A/H3N2 infection as relevant despite the emergence of drift strains, and the
fact that in the ≥65 years study, subjects were not classified as vaccine-matched.
Influenza occurrence first depends upon the exposure of a given population to circu-
lating viruses. Because countries have diverse vaccination policies that may influence
the transmission and exposure to influenza, we included season strength as a covariate
based on surveillance in each country as an indicator of exposure. However, exposure
may change the level of antibody needed to prevent illness of any severity; this is an
important concept, because in adults, most illnesses are relatively mild, but the risk
of severe illness resulting in hospitalization and adverse outcomes increases with age.
In this pooled analysis, we did not have systematic prospective classification of mod-
erate to severe illness, and as the antibody level correlating with protection against
moderate to severe illness may be lower than that required to protect against mild ill-
ness, this study may be confounded. Indeed, differences in vaccine efficacy arising
from regional and seasonal variability of multiple circulating viruses (with wide het-
erogeneity in prevalence and variations in the severity of influenza illness) are difficult
to account for in a correlates of protection analyses. This point will be discussed in
more details in the context of phase III VE trials in Chapter 6.
An objective of our analysis was to try to identify the HI titre that best separates the
two subject groups - protected and not-protected. By considering a ROC approach,
selecting a cut-off point involves a trade-off between sensitivity (the probability of
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a case being not-protected by having a titre below the threshold) and specificity (the
probability of a non-case being classified as protected by having a titre value above the
threshold). The Youden index gives the same weight to both sensitivity and specificity
as it defines the cut-off point as the titre value that maximizes the sum of the sensitivity
and specificity (Youden 1950; Kelly et al. 2008).
The Youden index method depends upon the separability of the protected and non-
protected populations. However, the rate of infection among subjects with low titres
may be strongly associated with the chance of exposure and disease prevalence, which
vary between seasons and locations and social behaviour. Therefore, the HI titre den-
sity curves for two subpopulations, the first comprised of subjects who were not in-
fected are the results of a mixture of subjects who were protected and the second
comprised of subjects who were not protected but were not sufficiently exposed to
be infected. Several methods have been proposed to account for this issue. First the
methodology we used relies on the belief that false negatives are likely to occur and
thus sensitivity (true cases) should determine the cut-off value. As well as Youden in-
dex in our study we reported the cut-off for 90% sensitivity, which was 453 in subjects
<65 years and 5120 in subjects aged ≥65 years in a high season.
Another analytical method, suggested by Dunning (2006), uses scale logistic regres-
sion modelling in which the probability of the subject developing influenza is the
probability that the subject is susceptible multiplied by the probability that suscepti-
ble individuals develop disease (Coudeville et al. 2010). In addition, Li et al. (2013)
developed a dichotomization method based on the maximisation of the correlation be-
tween the two populations and the dichotomous variable. In the non-cases population,
the methods included a parameter defining the probability that the observation arises
from the case population (unprotected but not exposed).
In our logistic regression model, we found that the baseline risk of disease was higher
for older than younger subjects and was higher in strong season than a moderate/low
season. Subjects with a greater baseline risk (i.e. older subject and/or in a strong
season) will need higher antibody titres to have the same level of protection as subjects
with a lower baseline risk, meaning that our model provides varying cut-off points
for protection. In our model, we did not find a significant interaction between post-
vaccination titres and subject-related covariates, although given the lack of power,
the results should be interpreted with caution. However, we did find as reported in
the literature that a four-fold increase in post-vaccination titres was associated with a
two-fold decrease in the risk of infection.
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3.3 Conclusion
While post-vaccination HI titres cannot be interpreted as a surrogate of protection
as defined by Qin et al. (2007), there seems to exist a positive consistent correlation
between this measure and the risk of symptomatic influenza. Thus, within a homo-
geneous population, people with higher post vaccination HI titres appear to be better
protected than those with lower HI titres. However, this relationship does not seem to
hold the setting of an heterogeneous population. In our analysis, we found that age
and the levels of exposure were related to varying risks of disease depending on the
post vaccination HI titres. Although HI titres seem to be a useful COP to help develop
a vaccine, they do not have a good predictive power for the occurrence of the disease
and should not be interpreted as useful in this manner. Finally, throughout the clini-
cal development of a new vaccine, we recommend the use of relative immunogenicity
protection criteria, i.e. seroconversion factors and rates instead of seroprotection rates.
In the next chapters, we will focus our attention to the third phase of the clinical
development of new vaccines.
Summary of Chapter 3
• Vaccine development against seasonal influenza is based on post vaccination HI
titres. However, an experimental vaccine formulated to increase the immuno-
genicity response has failed to show improved efficacy compared to a standard
of care
• Through the assessment of HI response as a COP in a post-hoc analysis of
a pooled dataset of four VE trials, we confirm the correlation between post
vaccination HI titres and risk of developing clinical infection
• We also found that the baseline risk of clinical disease depended upon the
age/trial and season strength taken as an indicator of exposure to the virus.
Consequently, we believe that a universal threshold of protection does not seem
achievable since the protection level depends upon other factors, such as sub-
jects characteristics and level of exposure. Relative immunogenicity protection
criteria, i.e. seroconversion factors and rates instead of seroprotection rates,
should therefore be preferred in the immunogenicity trials.
Chapter4
Influenza vaccine efficacy trials:
a simulation approach to
understand failures from the
past
This chapter is mainly based on the paper "Influenza vaccine efficacy trials: a sim-
ulation approach to understand failures from the past" by Benoit A., Legrand C. and
Dewé W., conditionally accepted by Pharmaceutical Statistics.
The success of a seasonal influenza vaccine efficacy trial depends upon the design but
also the annual epidemic characteristics. In this context, simulation methods are an
essential tool in evaluating the performances of study designs under various circum-
stances.
In this chapter, we discuss why traditional methods for simulating time-to-event data
are not suitable for the simulation of influenza vaccine efficacy trials. Instead, we
propose a mathematical model parameterized with historical surveillance data, het-
erogeneous frailty among the subjects, survey-based heterogeneous number of daily
contact and a mixed vaccine protection mechanism.
We illustrate our methodology by generating multiple trials data similar to a large
phase III trial that failed to show additional relative vaccine efficacy of an experi-
mental adjuvanted vaccine compared to the reference vaccine. We show that small
departures from the designing assumptions, such as a smaller range of strains pro-
tection for the experimental vaccine or the chosen endpoint, could lead to smaller
probabilities of success in showing significant relative vaccine efficacy.
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4.1 Introduction
In Chapter 3, we showed that while post vaccination HI titers do not predict the effi-
cacy of a vaccine there was still a correlation between the immunogenicity response
and protection against clinical influenza. Adjuvanted vaccine thus, formulated to in-
crease the immunogenicity response, should provide increased VE compared with a
standard vaccine. Unfortunately this could not be confirmed in the large Influence
65 trial. In the season 2008-2009 this large, multi-countries trial in the elderly (≥65
years) failed to show improved efficacy against all influenza A and B strains of a new
adjuvanted vaccine versus the standard vaccine (McElhaney et al. 2013). Because of
the study population, no placebo group could be included in the trial and all subjects
were vaccinated, either with the experimental vaccine or with the standard one.
Possible reasons for the failure of this trial include:
• The endpoint chosen for this trial was too ambitious: it had been assumed that
the adjuvanted vaccine would give protection against the vaccine strains but also
against other strains (excluding the pandemic strain)
• The absolute efficacy of the new vaccine was lower than expected while the
absolute efficacy of the reference vaccine was as expected, resulting in a lower
relative efficacy defined as the efficacy of the new vaccine compared to the
reference vaccine
In the recent years, multiple failures of influenza VE trials have been observed (Ohmit
et al. 2008; Beran et al. 2009b; Jackson et al. 2010; McElhaney et al. 2013; Tsang
et al. 2014). To learn from past failures and improve influenza vaccine development,
it is essential to understand what might have happened. Indeed, when designing and
analysing VE trials, complex issues related to particularities of influenza have to be
dealt with (see Chapter 2). Influenza viruses are constantly evolving, which makes
the intensity of the the seasonal epidemics and their predominant circulating strains
somewhat unpredictable (Gupta et al. 2006). As a lot of complex factors must be prop-
erly accounted for, sound, detailed, evidence-based planning is required to design and
conduct powerful clinical trials able to demonstrate efficacy of an experimental vac-
cine. Therefore clinical trials may fail to show significant VE for reasons other than
lack of efficacy, for example because of low virus circulation or mismatch between
the circulating and vaccine strains. In such a complex context, simulation studies are
a particularly useful tool to understand failure of past trials, to investigate the perfor-
mance of various designs and ultimately to help design high-quality trials (Burman
et al. 2005; Burman and Wiklund 2011).
Since the most fundamental piece of information collected in a VE study is the time of
onset of each influenza episode, simulating VE data means generating time-to-event
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data. Classical data generation techniques for time-to-event data are usually based on
simple models, such as the Cox proportional hazards (PH) model, assuming a para-
metric baseline function (Bender et al. 2005). However, we will show that such models
cannot appropriately take into account the fact that influenza yearly epidemics depend
on many factors. The particularities of influenza, such as seasonality, heterogeneity
of individuals and their level of exposure (Longini Jr and Halloran 1996), virus cir-
culation, mechanisms of vaccine protection (Smith et al. 1984; Halloran et al. 2010)
and regular mismatches between vaccine and circulating strains are not captured by
these models. We therefore propose a mathematical model inspired from the epidemi-
ological literature (Chao et al. 2010). Our objective is to generate data consistent with
the predominant characteristics of seasonal influenza to assess trial designs and data
analysis methodologies.
Section 4.2.1 describes characteristics of influenza are not reflected in classical data
generation methods. In section 4.2.2, we propose a new model and a new algorithm
allowing to take them into account.
Based on this, a simulation study is performed in Section 4.3 to show how it can
help better understanding the failure of the trial mentioned above. We simulate data
for similar trials, but adding a placebo group, and use these to investigate the impact
of the choice of the trial main endpoint, the range of protection of the new vaccine,
the presence of an immune portion in the population and of the real efficacy levels,
absolute and relative.
4.2 Background and context
4.2.1 Simulation state-of-the-art and particularities of in-
fluenza
In this section, we describe the particularities of influenza and its spreading dynamic.
We explain why these are not taken into account in the classical simulation time-to-
event models and how we include those characteristics in our proposed model. We
have selected influenza characteristics that appear to be relevant in regards to the out-
come of VE trials. Our objective is to build a data generation algorithm that can be
used to design a future VE trial. We intend our model to be relatively sraightforward
to use while remaining flexible enough to reflect various scenarios.
Several epidemiological models have been developed for infectious diseases. Their
main objective is to understand the spread of the diseases and the measures, such as
vaccination, needed to control their propagation. Among those models, we cite the
Susceptible-Infectious-Recovered (SIR) model (Coburn et al. 2009), a compartmental
model, and FluTE (Chao et al. 2010), a stochastic model specific to influenza epi-
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demics. None of those models however can be directly applied to generate clinical
trials data such as needed in our work. Indeed one of the main specificity of simu-
lating clinical trials data is that the trial population is homogeneous but has contacts
with an heterogeneous population. As a result, a large population would have to be
generated through an epidemiological model and the trial participants would then be
sampled within the sub-population of interest whereas our methodology allows the
direct simulation of only the trial participants.
Cox PH model
In the context of influenza VE trials, the time-to-event represents the time between
vaccination and event or censoring. Simulating influenza VE trials requires a model:
the parametric proportional hazard regression (Cox 1972) is frequently used to simu-
late data. Any covariate is supposed to have a multiplicative effect with respect to the
baseline hazard function and, given the covariates, subjects are assumed to have the
same risk of event.
Seasonality and geographical regions heterogeneity
Influenza infections are characterized by seasonality. The clinical influenza incidence
curve over time is almost flat during most of the year and present one or more peaks
between November and March in the Northern Hemisphere and between May and
October in the Southern Hemisphere (Figure 4.1)(Lofgren et al. 2007).
Traditional parametric survival time distributions, such as exponential, Weibull and
lognormal densities are characterized by one or two parameters (Burton et al. 2006).
Those distributions are characterized by a constant or unimodal hazard function. How-
ever, identifying the distribution that would fit the timing and intensity of the peak is
neither flexible nor straightforward. Three-parameters extension of those distribu-
tions (Cooray 2006; Reed 2011) and polyhazards models (Tsai et al. 2013) have been
developed to improve the flexibility of the hazard functions, allowing multimodal haz-
ards. The piecewise exponential distribution (Demarqui et al. 2008; Kim and Proschan
1991) is another flexible option for modelling time-to-event data. The difficulty in
generating data when using these flexible parametric distributions lies in the selection
of the parameters and in the case of the piece-wise model, the determination of the
hazard change points.
Therefore, in this context, a parametric baseline hazard shape is not recommended to
generate data. Instead, we propose to use incidence historical data, available in epi-
demic surveillance databases such as FluNet (Flahault et al. 1998). This methodology
will be detailed in Section 4.3.
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Figure 4.1: 2013-2014 flu seasons in four countries: at the top, two from the Northern
hemisphere (Belgium and US) and at the bottom, two from the Southern hemisphere
(Australia and South Africa). The colors of the bars represent the virus strains. From
the FluNet website.
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This proposal makes the inclusion of the multiplicity of the strains causing yearly epi-
demics straightforward. Indeed since influenza is not a single, genetically stable virus:
several strains co-circulate and the viruses mutate continuously. The repartition of the
strains and their level of circulation differ between geographical regions, resulting in
varying times of occurrence and magnitudes of epidemic peaks (Dewé et al. 2013).
Generating data using a parametric baseline hazard function for different influenza
sub-types and geographical regions would require the selection of parameters for each
strain and for the assumed correlation structure between the regions. Instead, we use
country specific and strain specific historical incidence data to take into account the
geographical aspects of the circulation and the repartition of the strains.
Subjects fragility
Not everybody is equally affected by influenza (Chapter 2) while traditional methods
of simulation for time-to-event assume an equal risk for all subjects given the covari-
ates. In the seasonal influenza context, this is not verified as unobserved sources of
heterogeneity, such as subject fragility, must be taken into account. We propose to
include subject weakness and contact rate random effects through:
λ(t|Z = z,X1 = x1, X = x) = zh(t|X1 = x1, X = x) (4.2.1)
where z is an unobservable realization of a non-negative random variable with a given
probability density function fZ . The random variable z is often called a frailty (as
people with a higher value will have a higher hazard, and thus be more "frail") and
model (4.2.1) is then referred to as the frailty model (Duchateau and Janssen 2007).
Contacts
Influenza infection is conditional to virus exposure, i.e. contact with an infected per-
son. The higher the number of contacts, the higher the risk of infection. The daily
contact rate can be modelled from a discrete distribution. Selecting a distribution
admitting mass at 0 allows for the inclusion of subjects who are not exposed at all.
For the purpose of our model, we consider that the number of daily contacts for one
individual is constant across time.
Vaccine protection mechanisms
The PH model actually assumes that all the vaccinated individuals are equally pro-
tected against the virus via the factor exp(β1) (Equation 2.2.10 in chapter 2) acting
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multiplicatively on the baseline hazard. However, the existence of two mechanisms
of vaccine protection, leaky and all-or-none, has been argued (see Chapter 2 for more
details).
Arguing that vaccine protection is likely to be a mixture between both leaky and all-or-
none mechanisms, we introduce the two protection mechanisms in our model (Figure
4.2). Consequently, individuals from the experimental group have either a complete
or a partial protection against the studied viruses. Furthermore, we consider that some
subjects could be previously immune to the infection, for example because of prior
vaccination or influenza infection with a genetically closely related virus strain. We
consider that a portion pi0 (pi0 ≥ 0) of the subjects from the reference group is com-
pletely protected. This fraction is increased by an additive efficacy term VEpi in the
experimental group resulting in a fraction pi1 of non-susceptible subjects in this group.
We therefore use two efficacy parameters (Halloran et al. 1996). First, VEs represents
the vaccine protection in the experimental versus the reference group in the suscepti-
ble population. Second, VEpi represents the proportion of the vaccinees totally pro-
tected that is induced by the experimental vaccine. The proportion of subjects totally
protected in the experimental group is computed as pi1 = pi0 + V Epi where pi0 is pro-
portion of subjects totally protected in the reference group. Total efficacy is computed
as
1− (1− V Es) (1− pi1)
1− pi0 (4.2.2)
In the case of a leaky vaccine, pi1 = 0 and VE resumes to VEs. If the vaccine only act
as an all-or-none protection, VEs = 0 and V E simplifies to 1− 1−pi11−pi0 .
4.2.2 Simulation Framework
Based on the previous points, we generate times of disease onset through a mixture
cure model based on the principle that there are three conditions for any subject to get
influenza: first he/she must be susceptible, second he/she must enter in contact with an
infected person, and third transmission of the virus must occur (Halloran et al. 1991).
We consider a sample of n independent individuals participating in a phase III VE
trial. The subjects are potentially exposed to the infectious agent of interest over a
period of time [0, T ], where T is the end of the surveillance period. So T is also a
censoring time for the subjects without influenza episode. The model could easily be
extended to the case of non-informative random censoring. Subjects are randomized
to receive either the experimental or the reference vaccine.
In our model, a subject i (i = 1, ...n) has contact with other persons at a rate of ci
contacts per unit of time. The probability at time t that a contact is infectious for
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Figure 4.2: Illustration of Mechanisms of Vaccine Efficacy (adapted from Halloran
et al. (Halloran et al. 2010)): distribution of susceptibility in the control (top) and
new vaccine (bottom) groups of subjects. A fraction pi0 of the subjects are completely
protected in the reference (placebo or active control) group. This fraction is increased
by VEpi in the experimental group, resulting in a fraction of totally protected subjects
of pi1. The level of susceptibility of the remaining 1− pi1 experimental group subjects
is reduced by a factor VEs compared to the reference group ones.
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influenza strain k is defined by the prevalence of the disease caused by strain k at time
t, pk(t), k = 1, ...K. If a susceptible reference group person makes a single contact
with a person infected with the pathogen of interest, then he/she becomes infected
with probability ρ, which is the transmission probability to a reference group person.
If a person from the experimental makes a single contact with an infected person,
then that individual becomes infected with rate (1− V Es) ρ. The fragility term for
subject i is noted zi. It acts as a multiplier of the instantaneous hazard. To simplify
the notation we consider a 1 : 1 ratio and, for each vaccine group, i goes from 1 to
n
2 . So, the instantaneous hazards h0,k,i(t) and h1,k,i(t) for strain k at time t for the
reference and experimental group subjects respectively are:
{
h0,k,i (t) = (1− ω0,i)ziciρ pk (t)
h1,k,i (t) = (1− ω1,i) {(1− V Es) ziciρ pk (t)}
(4.2.3)
i = 1, ..., n2 with g = 0, 1 for the reference and the experimental group respectively,
t = 1, ..., T , the protection status ω0,i ∼ Bernouilli(pi0) for the reference group and
ω1,i ∼ Bernouilli(pi0 + V Epi) for the experimental group.
The overall survival function for subject i, Sg,i(t), for any strain, can be derived as:

S0,i (t) = exp
− (1− ω0,i)
ziciρ∑
k
 t∫
0
pk (u) du

S1,i (t) = exp
− (1− ω1,i)
(1− V Es) ziciρ∑
k
 t∫
0
pk (u) du

(4.2.4)
If we consider daily prevalences for the investigated strain(s), the integral of pk(u),
i.e. the cumulative prevalence of the infection, is approximated through the cumulative
sum of the daily prevalences of infection between time 0 and time t.
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Unconditionally to the susceptibility status ω and for all circulating strains, we have
for the comparator group
Pr(T ≥ t|X1 = 0)
= Pr(T ≥ t|ω0 = 0, X1 = 0)× Pr(ω0 = 0|, X1 = 0)
+ Pr(T ≥ t|ω0 = 1, X1 = 0)× Pr(ω0 = 1|, X1 = 0)
= Pr(T ≥ t|ω0 = 0, X1 = 0)× (1− pi0) + pi0
= exp
[
−
∫ t
0
(h(u|ω0 = 1, X1 = 0)du)
]
× (1− pi0) + pi0
= exp
[
−ziciρ
∫ t
0
(p(u))du)
]
× (1− pi0) + pi0
(4.2.5)
and for the experimental group
Pr(T ≥ t|X1 = 1)
= Pr(T ≥ t|ω1 = 0, X1 = 1)× Pr(ω1 = 0|, X1 = 1)
+ Pr(T ≥ t|ω1 = 1, X1 = 1)× Pr(ω1 = 1|, X1 = 1)
= Pr(T ≥ t|ω1 = 0, X1 = 1)× (1− pi1) + pi1
= exp
[
−
∫ t
0
(h(u|ω1 = 1, X1 = 1)du)
]
× (1− pi1) + pi1
= exp
[
−(1− V Es)ziciρ
∫ t
0
(p(u))du)
]
× (1− pi1) + pi1
(4.2.6)
We can see that for t→ +∞ the marginal survival functions converge respectively to
pi0 and pi1 in the comparator and the experimental vaccine groups.
4.3 Illustration
Our simulation methodology is very flexible and can be used in many situations. For
example, through the strain-specific capacity of our simulation framework, the benefit
of adding a fourth strain in the seasonal vaccines could be assessed. It is also a power-
ful tool for designing trials since it allows to generate multiple scenarios and to test the
robustness of the chosen design and statistical analysis model in different situations.
In the next section, we illustrate how our simulation model is used as a retrospec-
tive tool. We show how it can be used to better understand the outcome of the trial
mentioned earlier (and described in more details below). Simulations will be used to
investigate the likelihood of three possible scenarios (primary endpoint too ambitious,
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higher VE for the control than expected, lower VE for the experimental vaccine than
expected) and their potential impact on the results. To do so, we will simulate data for
trials designed like the original trial and ran during the same season and in the same
countries but we will artificially include patients in a placebo group in these trials.
4.3.1 Original trial
The trial of interest included 43802 subjects aged over 65 from 15 countries worldwide
during the 2008-09 influenza season. Subjects were randomly assigned (1:1) to receive
either an adjuvanted new trivalent vaccine or the standard non-adjuvanted trivalent
vaccine. The observation period started on November 15, 2008 and ended on April
30, 2009. The primary endpoint was the relative efficacy of the new vaccine versus
the standard vaccine for the prevention of laboratory confirmed influenza A and B.
The study protocol foresees a Cox regression analysis model including the covariates
vaccine and country.
The trial was powered based on a power of 90% to confirm the relative vaccine efficacy
with a one-sided type 1 error of 2.5% for an expected cumulative incidence of clinical
infection during the observation period, i.e. AR of 1% in the group receiving the
standard vaccine. It was assumed that the absolute efficacy for the new vaccine was
65% and 50% for the standard vaccine (relative efficacy of 30% for the new versus the
standard vaccine).
This trial is registered with ClinicalTrials.gov, number NCT00753272 and has been
published recently (McElhaney et al. 2013).
4.3.2 Simulated trials
We implemented our simulation methodology in SAS v.9.3. Data analysis can be done
in SAS or in R v3.0.1 within the IML SAS to R capacity.
Our data generation algorithm is summarized in figure 4.3. All model parameters
are combined according to equation 4.2.4, resulting in n individual survival curves. A
random [0, 1] uniform number ui is generated for each subjects and disease occurrence
time is defined as min {t : ui ≤ Si(t)}. Observations are censored at the end of the
trial. We consider that once a subject has been infected by any strain, he/she is immune
for the rest of the season.
Contrarily to the traditional methodology, our simulation method requires the genera-
tion of individual survival curves. However, if one simulates the data effectively, the
process is neither time nor memory consuming.
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Figure 4.3: Data generation algorithm. Steps above the dashed line are performed
once while steps below are performed for each simulation.
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Trial design
We simulate trials over a single season including 43802 subjects (as in the original
trial) plus 21901 subjects for the new placebo group, i.e. 65703 subjects equally allo-
cated between 3 vaccine groups (placebo, standard vaccine and adjuvanted vaccine).
Country representation and ages of the subjects are similar to the characteristics of the
original trial.
Absolute VEs are defined as the hazard reductions between each vaccinated groups
and the placebo group, estimated through a Cox regression model with vaccine and
country as covariates. Relative VE is the risk reduction between the adjuvanted vac-
cine group and the standard vaccine group.
For each scenario, 500 trials are generated.
Note: number of simulations
Following Burton et al. (2006), we calculated the number of simulations required to
obtain estimates within 5% accuracy of the assumed true value for the vaccine effect,
β1. The number of simulations to perform, B, is calculated as
B =
(
Z(1−α2 )σ
η
)2
(4.3.1)
where η is the specified level of accuracy from the true value β1, Z(1−α2 ) is the 1− α2
quantile of the standard normal distribution and σ2 is the variance of the parameter of
interest.
For an expected vaccine effect β1 = −0.69 (VE=0.5), 100 expected events, σ2 = 0.04
and α = 0.05, the required minimum number of simulations is 125. With 250 and 500
simulations, the estimates obtained are within respectively 3.5% and 2.5% of accuracy
of the assumed true value for the vaccine effect.
Vaccine efficacy
We consider seven combinations of efficacy levels of the two vaccines: the assumed
scenario for the original trial design, two scenarios with lower than expected absolute
efficacy for the standard vaccine and four scenarios in which the absolute efficacy of
the standard vaccine is as expected but the efficacy of the new vaccine is lower than
assumed.
Vaccine protection tends to be smaller for elderly compared to young adults and in this
age group total protection is very unlikely (McElhaney et al. 2006). For this reason,
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Cases considered
Standard Adjuvanted for the computation
Scenario vaccine vaccine of VE
Mixed Vaccine All All
strains strains cases
Trivalent Vaccine Vaccine All
all cases strains strains cases
Trivalent Vaccine Vaccine Matching
matching cases strains strains vaccine strains
Table 4.1: VE scenarios simulated in terms of vaccine protection and cases considered
we only consider a leaky protection mechanism. In a first setting, we consider that
all subjects in the control group are susceptible (pi0 = 0) and in a second setting we
consider that because of their age thus prior influenza experience, the population of
interest includes 20% of immune subjects.
The two vaccines administered in the original trial contain three influenza strains: a
H1N1 A strain, a H3N2 A strain and a Yamagata lineage B strain. We consider that the
standard vaccine only gives protection against those three strains. For the adjuvanted
vaccine, we consider two cases: in the first one we simulate data considering that this
new vaccine only protects against the strains it contains, as the standard vaccine. In
the second one, we consider that the adjuvant additionally provided cross-protection
against the strains not included in the vaccine (except the H1N1 pandemic strain that
started circulating by the end of the season 2008-2009 in some countries). In the first
case, we compute VE against all cases considered and VE against vaccines strains.
Table 4.1 shows the three VE scenario simulated for all the levels of efficacy consid-
ered.
Virus circulation
We use historical data from FluNet (Flahault et al. 1998) for season 2008-09 for the
original trial 15 countries.
We consider viral circulation to be proportional to the weekly percentage of tests pos-
itive for each strain. This quantity is divided by a constant calibrated to reach desired
overall seasonal AR levels, here 2%. Daily strains prevalences are computed from the
weekly incidences and average disease duration.
Daily contacts rate
Mossong et al. (Mossong et al. 2008) showed that the best model for contacts hetero-
geneity is a negative binomial density, characterized by mean µ and over-dispersion
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parameter φ. They also found that numbers of contacts differed between countries
and age categories. The probability of observing a non-negative number of daily con-
tacts ci for a subject i characterized by explanatory variables Xi follows a negative
binomial distribution with mean µ varying with Xi and over-dispersion parameter φ.
Over-dispersion parameter value is set as φ = 10.36 and values for the specific age
category (≥ 65) and 15 countries mean numbers of daily contacts µ are derived from
Mossong et al. (Mossong et al. 2008) whenever available. Number of daily contacts
mean values for the other countries were made up in order to maintain variability in
contacts rates in our samples.
Frailty
Fixed effects estimations have been shown to be robust to frailty strictly-positive dis-
tributions mispecification in a frailty model (Pickles and Crouchley 1995). The choice
of the frailty distribution is therefore not of particular interest here. We make the clas-
sical choice of the continuous strictly positive one-parameter gamma distribution:
fZ(z) =
z
1
δ−1 exp(−zδ )
δ
1
δ Γ( 1δ )
(4.3.2)
with Γ the gamma function and δ the variability parameter. We fixed δ = 4 in order
to reflect a 10-fold risk difference between the mean and the percentile 99 subjects,
translating large fragility differences between healthy subjects and subjects with con-
comitant co-morbidities (Figure 4.4).
Transmission probability
In epidemiological models, the spread of a disease is usually characterized by the
basic reproduction number R0. It is defined as the number of secondary infections
that arise from a typical primary case in a completely susceptible population (Truscott
et al. 2011). R0 is a combination of the number of contacts per unit of time per
individual, here the mean number of daily contacts, c, the probability ρ of transmitting
the infection per infectious contact and the mean duration τ of the infection period (Eq
4.3.3).
R0 = cρτ (4.3.3)
We consider that a subject infected with influenza is contagious for a period of 7 days
(CDC 2011) and that the average number of contacts for an infectious subject is 18
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Figure 4.4: Gamma density with δ = 4. The dashed line indicates the percentile 99.
(Mossong et al. 2008). The reproductive number for influenza has been estimated as
ranging from 1 to 2, depending on the epidemic strength (Truscott et al. 2011). In
order to reflect this information, a transmission probability ρ = 0.01 seems realistic.
4.3.3 Results
For each scenario, we estimate the VE of the adjuvanted vs. the standard vaccine
through a Cox regression model with vaccine and country as covariates, as in the orig-
inal trial. In table 4.2, we report the median estimate with 95% simulation confidence
interval, defined as the 2.5 − 97.5 inter-percentile range of the estimated values. We
define the probability of success, P(success), as the proportion of simulated trials in
which the lower limit of the 95% confidence interval is greater than 0.
In the season 2008-2009, influenza A H3N2 mainly circulated in the European coun-
tries, H3N2 and B strains in Canada, B strains in Mexico and the US and seasonal
H1N1 in Asia (McElhaney et al. 2013). The Yamagata B strain was included in the
vaccine, but mostly Victoria B strain (the other B lineage) circulated, which led to
mismatch (Reed et al. 2012). Those characteristics are well captured in our simu-
lations. The H1N1 pandemic strain also appeared at the end of the season in some
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countries. However, as in the original protocol, it was decided not to take into account
those cases in the analyses.
The original trial was designed assuming AR of 1% in the standard vaccine group. In
our simulations, AR are calibrated for the placebo group. We obtain matching cases
AR of 1.4% and 1.1% respectively when all subjects are susceptible and when 20% of
them are immune. Similarly, when considering all cases (matching and non matching),
AR of 2.2% and 1.7% are obtained in the placebo group without and with an immune
fraction. Consequently, AR in the standard vaccine group under trial assumptions
(absolute VE of 50% for the standard vaccine) are similar to the value of 1% used in
the design step of the original trial.
In the situation where all trial assumptions are met (Mixed scenario in Table 4.2),
computed relative VE results not only from higher efficacy of the new vaccine over the
standard one for the vaccine strain (simulated relative VE, from 0 to 0.3) but also from
the protection of this new vaccine against non vaccine strains (relative VE equal to the
absolute VE). Median relative VE, simulation empirical 95% CI and probabilities of
success (significant relative VE) are presented in Table 4.2. In this case, estimated
relative VE against all strains is higher than the simulated relative VE against the
three vaccine strains, resulting in higher probabilities of success to detect a significant
gain of efficacy for the adjuvanted vaccine compared to the standard one, event if
the relative VE against the vaccine strains is not as high as expected. This is clearly
the result of the additional protection of the adjuvanted vaccine against the second B
strain.
If both vaccines protect only against the three vaccine strains they contain (Trivalent
scenario in Table 4.2), VE against all influenza cases, as in the original trial protocol,
are lower than expected due to the mismatch between the vaccine and the circulat-
ing B strains. At the expected VE levels, the probabilities of success in showing an
additional gain of the adjuvant is only 48% for a median estimated relative VE of 0.15.
Finally, when both vaccines protect only against the vaccine strains and only match-
ing cases are considered for the analyses (Trivalent Match scenario in Table 4.2), the
median estimated relative VE are very close to the simulated values and the probabil-
ities of success are high (82% if all subjects are susceptible). Decrease in relative VE
however results in smaller vaccine effects and consequently much lower probabilities
of success.
In all cases, the presence of an immune fraction pi0 = 0.2 leads to a smaller number
of cases than expected and thus smaller probabilities of success. When the absolute
VE of the standard vaccine is smaller than assumed but the relative VE of the new
vaccine is as expected, all other parameters being equal, the number of cases is higher
resulting in higher probabilities of success.
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Stand. vs. Adj. vs. Est. Adj. 2.5%-97.5%
VE scenario Pbo Stand.1 pi0 vs. Stand.2 percentiles P(success)
Mixed 0.50 0.30 0 0.45 0.34, 0.55 1
0.2 0.45 0.32, 0.56 1
0.10 0.30 0 0.31 0.20, 0.41 1
0.2 0.32 0.19, 0.42 0.99
0.30 0.30 0 0.36 0.25, 0.46 1
0.2 0.37 0.24, 0.47 1
0.50 0.25 0 0.41 0.29, 0.52 1
0.2 0.41 0.28, 0.53 1
0.50 0.15 0 0.34 0.20, 0.45 1
0.2 0.34 0.19, 0.46 0.99
0.50 0.05 0 0.26 0.12, 0.38 0.93
0.2 0.27 0.11, 0.40 0.88
0.50 0 0 0.22 0.08, 0.35 0.81
0.2 0.24 0.07, 0.37 0.74
Trivalent 0.50 0.30 0 0.15 0.00, 0.28 0.48
0.2 0.15 -0.03, 0.30 0.39
0.10 0.30 0 0.20 0.07, 0.30 0.82
0.2 0.20 0.06, 0.32 0.76
0.30 0.30 0 0.17 0.04, 0.29 0.66
0.2 0.18 0.02, 0.31 0.60
0.50 0.25 0 0.12 -0.04, 0.26 0.35
0.2 0.13 -0.05, 0.28 0.31
0.50 0.15 0 0.07 -0.10, 0.21 0.15
0.2 0.07 -0.11, 0.23 0.13
0.50 0.05 0 0.03 -0.14, 0.17 0.06
0.2 0.03 -0.17, 0.19 0.05
0.50 0 0 0 -0.18, 0.15 0.02
0.2 0.01 -0.19, 0.17 0.02
Trivalent Match 0.50 0.30 0 0.29 0.10, 0.44 0.83
0.2 0.29 0.07, 0.46 0.68
0.10 0.30 0 0.29 0.15, 0.41 0.97
0.2 0.30 0.14, 0.43 0.93
0.30 0.30 0 0.29 0.13, 0.42 0.89
0.2 0.29 0.11, 0.44 0.84
0.50 0.25 0 0.24 0.04, 0.40 0.64
0.2 0.25 0.02, 0.42 0.55
0.50 0.15 0 0.15 -0.07, 0.32 0.27
0.2 0.15 -0.10, 0.35 0.22
0.50 0.05 0 0.04 -0.20, 0.23 0.06
0.2 0.06 -0.21, 0.27 0.06
0.50 0 0 -0.01 -0.26, 0.19 0.02
0.2 0 -0.27, 0.22 0.02
1 Additional protection of the adjuvanted vaccine against the vaccine strains.
2 Estimated additional protection of the adjuvanted vaccine against all strains (mixed
and trivalent scenarios) or vaccine strains (trivalent match scenario)
Table 4.2: Estimated VE of the adjuvanted vaccine (Adj.) vs. the standard vaccine
(Stand.): median estimates with the 2.5-97.5% inter-percentile range of the estimated
values and proportions of simulated trials in which VE is significantly greater than 0,
at the 95% confidence level.
4.4. Discussion 63
While our simulated trials do not perfectly match the characteristics of the original
trial, we show that departure from the hypotheses set in the design stage rapidly lead
to smaller probabilities of success than expected. Because of the uncontrolled issues
that can occur during one influenza season, such as mismatch between vaccine and
circulating strains, one has to be cautious when designing a VE clinical trial. The
impact of such departures should therefore be thoroughly studied and designs allowing
to decrease the risk of failure should be preferred. For example, we recommend that
trials be conducted over several seasons. Also, our simulation results weigh in favour
of the development of quadrivalent seasonal influenza vaccines which contain both B
strains thus limiting the risks of mismatch.
4.4 Discussion
In the epidemiological context, simulation models have been developed in order to
study the spread of influenza across networks (Chao et al. 2010). In those models,
individuals are related through a social network where influenza spreads, travelling
from person to person. In clinical trials however, subjects are not related and the so-
cial course of the disease (who catches the disease from whom) is not known. One
of our main contributions relies upon our use of historical data in order to get around
this unknown information. It should be noted that while our simulation model is in-
spired by the epidemiological models, we do not aim at capturing all the details of the
real situation. Our objective is rather to obtain data consistent with the predominant
characteristics of seasonal influenza.
Following Halloran et al. (1996), we define disease occurrence as the combination of
the exposure to infection and the susceptibility of the subject. Exposure to infection
is relative to the rate of contact, the prevalence of the infection among the population
and the infectiousness of the disease. Susceptibility is a function of individual fragility
and vaccine protection.
Our simulation method is a flexible and powerful tool. It allows to design and to
question the probability of success of seasonal influenza VE trials under varying con-
ditions: design over one vs. several influenza seasons, varying statistical analysis
models (Benoit et al. Conditionnaly accepted), good matching season vs. mismatch-
ing, homogeneous vs. heterogeneous populations etc. It has the advantage of first not
requiring a parametrical shape for the baseline hazard and second of including several
sources of heterogeneity. Also, the inclusion of strain specific information allows the
assessment of the impact of mismatching on the power of the design.
One possible specific application of our methodology, as illustrated in this chapter,
is to retrospectively identify potential sources of problem for a large trial that failed
to show significant additional gain of VE for a new adjuvanted vaccine compared to
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the standard vaccine. We added an additional placebo group to the trial, which was
not ethically acceptable in reality due to the level of fragility of the population of
interest. We were able to simulate different scenarios of vaccine protection for the
adjuvanted vaccine, both in terms of relative VE but also with different hypotheses of
strains protection range. We clearly showed that small departures from the assumed
hypotheses could rapidly lead to smaller probabilities of success and that the choice
of the primary endpoint (all cases or only matching cases) was crucial.
When designing future trials, our proposed strategy consists of using past data in order
to predict a range of possible outcomes. So in order to select an efficient study design,
we suggest to run simulations based on data from several historical seasons. By test-
ing the design over both typical virus circulation years and more unusual seasons,
such as season 2009-2010, characterized by the H1N1 pandemic, the probability of a
successful trial in different contexts can be assessed. Sources of data used to simulate
the prevalence of the disease among the studied population can be historical databases
but also information from previous clinical trials.
Finally, while we developed this method in the context of seasonal influenza, it could
be applied to any other airborne transmission disease such as tuberculosis (Ulrichs
2010) or pertussis (Longini Jr and Halloran 1996) with limited adaptations.
4.5 Conclusion
In this chapter, we developed a methodology based on a simulation model. Our model
is a flexible and a powerful tool to design new VE trials. As an illustration, we
explored the impact of departures from the protocol hypothesis on the probabilities
of success of phase III VE trials. We found that even small departure from the as-
sumptions, especially at the strains protection level, could result in much decreased
probabilities of success. Our recommendation is to conduct sensitivity analyses when
designing a trial by simulating several scenarios.
In the next chapter, we will use our simulation framework to assess the performances
of the classical regression models in estimating seasonal influenza VE.
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Summary of Chapter 4
• Symptomatic influenza depends upon exposure to the virus, transmission of the
virus, fragility of the host and vaccine protection. Fully parametrical simulation
models do not take into account those particularities.
• We developed a flexible model for the simulation of flu VE data, including
strains information and historical data.
• We illustrated our methodology by re-simulating a large failed phase III trial
and we showed that small departures from protocol assumptions rapidly led to
decreased power to show significant VE.
• We recommend to conduct sensitivity analyses when designing an influenza
vaccine trial and our simulation algorithm is a powerful tool to accomplish this
goal.
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Chapter5
Performances of regression
models in estimating seasonal
influenza vaccine efficacy
This Chapter is mainly based on the paper "Performances of regression models in es-
timating communicable infectious diseases vaccine efficacy" by Benoit A., Legrand C.
and Dewé W., and submitted to PLOS One.
Vaccine efficacy is classically estimated through logistic, Poisson or Cox regression
models. The use of those models is increasingly being challenged in the context of
seasonal influenza, where sources of heterogeneity are multiple. Indeed, seasonal
patterns, subject heterogeneity, exposure effects and vaccine protection mechanisms
conflict with models assumptions and as a result, the estimates of vaccine efficacy
could be biased.
In this chapter, we investigate whether this omission of sources of heterogeneity would
lead to biased estimates. We use our simulation model in two complementary ap-
proaches. First, we derive the marginal vaccine efficacies for different heterogeneity
settings. Second, we perform a large simulation study to examine the quality of vac-
cine efficacy estimates obtained from the regression models when sources of hetero-
geneity are omitted.
We show that the estimates are indeed biased and that the magnitude of the bias is
related to the incidence of the disease. However, at low attack rates, biases are small
and not clinically relevant.
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5.1 Introduction
To estimate VE against seasonal influenza, clinical trial data are classically analysed
using logistic, Poisson or Cox regressions models, adjusting for potential confounders
(Nauta 2010; Halloran et al. 1996) and including vaccine group as a fixed effect co-
variate. However, the assumptions of these regression models are increasingly being
challenged in the context of infectious diseases like seasonal influenza (Dewé et al.
2013). As a result, when designing such trials, long discussions between the man-
ufacturers and the regulatory authorities are often engaged to justify the correct use
of the selected model. Indeed, VE estimation iscomplicated by the seasonality of the
epidemics (Grassly and Fraser 2006), low AR (Atkinson et al. 2011), subject hetero-
geneity (Struchiner and Halloran 2007; Michiels et al. 2005; McElhaney et al. 2006;
Dewé et al. 2013) and variable mechanisms of vaccine protection (Smith et al. 1984).
Consequently, the assumptions of the classical statistical models do not always hold
and there is concern about biased estimates of VE.
The objective of this Chapter is to assess the quality of the VE estimates from the
classical models when these particularities are not taken into account. While this has
already partially been discussed (Bretagnolle and Huber-Carol 1988; Lachin 2011),
there is clearly a need to assess the magnitude of the biases and their specific impact
on seasonal influenza VE trials.
We first briefly describe the classical models for the estimation of VE and the issues
risen in the context of seasonal influenza. We then show that time-constant VE (no
waning) at the individual level, i.e., conditional VE, is associated with time-dependent
population-averaged VE, i.e. marginal VE, when the risk of disease is heterogeneous
among the individuals. We next perform a large simulation study where seasonal
influenza trials efficacy data are generated through the algorithm presented in Chapter
4 (Benoit et al. Conditionnaly accepted) and analysed with regression models omitting
sources of heterogeneity. We also discuss the applicability of more complex models,
univariate frailty and cure models and of a more simple model, a fully parametrical
survival model assuming constant risk over time. In the last section, we discuss our
results and the limitations of our work before suggesting further perspectives.
5.2 Methods of analysis and issues
5.2.1 Classical models
In VE trials for seasonal influenza, the endpoint of interest is the occurrence of well-
defined events such as laboratory-confirmed cases of influenza illness. Logistic, Pois-
son and Cox regressions are the most often used regression models to estimate VE.
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These models are presented and discussed in Chapter 2 and a brief overview of gen-
eral formulation is presented in Chapter 2. Each model is characterized by a different
approach to modelling of this endpoint, respectively cumulative incidence, incidence
taking into account the time of exposure, and time-to-event.
5.2.2 Issues with the classical models
Logistic, Poisson and Cox regressions all assume a multiplicative effect of vaccine on
the baseline risk of disease. Time of exposure is not taken into account in the logistic
model. In VE trials however, time of exposure is usually very similar between subjects
as accrual is done over a very short period and observation times are usually short (e.g.
one season), leading to very low drop-out rates. The three models are thus expected
to perform similarly with regards to exposure.
Seasonal influenza is characterized by a periodic surge in disease incidence (Grassly
and Fraser 2006). Those seasonal variations may be an issue for the logistic and the
Poisson regression models as they assume a constant rate of event within the period
of observation. However, it does not affect the semi-parametric Cox regression model
which allows a time-varying baseline risk when all subjects enter the observation pe-
riod at the same time.
An important characteristic of seasonal influenza is a low annual incidence rate (Atkin-
son et al. 2011). By the end of the annual season, less than 5% of the population have
been infected. In the specific case of constant baseline risk, short follow-up times, low
incidences and small RR associated with the risk factors the three regression models
have been shown to lead to similar estimates of VE (Frome 1983; Callas et al. 1998;
McNutt et al. 2003). When the outcome is more frequent, the OR is no longer a good
approximation of the RR. In this situation, erroneously relying on the OR winds up
overestimating the association between the covariate and the outcome (Zhang and Kai
1998).
The three models make the assumption that, given the covariates, observations are
independent and identically distributed. In the context of vaccination, unobserved
heterogeneity sources may cause the subjects to have various levels of fragility to the
disease. When inter-subjects heterogeneity exists, this assumption is not verified and
biased VE estimates may be obtained (Wienke 2010).
Regarding the mode of action of the vaccine, as mentioned in Chapter 2, there is most
probably a mixture of partial protection and complete protection . The population
under study thus combines a totally immune and a partially immune sub-populations.
None of the studied models is adapted in this situation (Halloran et al. 1992). One
solution would be to combine the logistic regression with a model accounting for the
time of exposure. The mixture cure model (Boag 1949; Berkson and Gage 1952)
makes such a combination. However, it requires sufficient follow-up to differentiate
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between the non-susceptible fraction and the susceptible who have not been exposed
enough. In clinical trials for VE against seasonal influenza, the follow-up is too short
to make this distinction.
5.3 Conditional versus marginal VE
Conditional VE is the efficacy at the individual level, i.e. conditional on the individ-
ual characteristics. Marginal VE is the averaged VE at the population level. In this
section, we show that time-constant individual VE is associated with time-dependent
population-averaged VE when the risk of disease is heterogeneous among the individ-
uals.
In Tournoud and Ecochard (2008), the authors develop alternative distributions for the
promotion time cure model. They derive marginal survival function for four distribu-
tions including Bernoulli and the negative binomial. In order to derive the marginal
time-dependent VE for different types of heterogeneities, we follow their methodol-
ogy by considering the general model:
hcond(t|ψ) = ψhcond(t) (5.3.1)
where hcond(t|ψ) is the conditional hazard function of developing influenza at time t
and ψ is a latent heterogeneity variable. The marginal survival function of developing
a influenza is:
Spop(t) = Eψ (Scond(t|ψ))
=
∫ ∞
0
Scond(t|u)fψ(u)du
=
∫ ∞
0
exp (−Hcond(t|u)) fψdu
=
∫ ∞
0
exp (−Hcond(t)u) fψdu
= Lψ(Hcond(t))
(5.3.2)
where Lψ denotes the Laplace transform of ψ (Tournoud and Ecochard 2008).
We apply this transformation to the model developed in Chapter 4 for 3 mechanisms
of heterogeneity at the individual level: a strictly positive continuous frailty term,
z, a fraction of non-susceptible subjects, pi and a positive discrete fragility term ci.
We combines them in an individual time-to-event data generation model. We define a
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mixture cure model based on the principles that to get symptomatic influenza a subject
must be in contact with an infected person, must be susceptible and transmission must
occur (Halloran et al. 1996; Benoit et al. Conditionnaly accepted). In our model, zi
represent the susceptibility of a subjects for example through his/her immunological
profile, pi0 and pi1 are respectively the proportions of immune subjects in the reference
and the experimental groups and ci is the number of daily contacts that are relevant
to influenza transmission. To simplify the notation we consider a 1 : 1 ratio and, for
each vaccine group, i goes from 1 to n2 .
hi,0 (t) = (1− ωi,0) {ziciρ p (t)}
hi,1 (t) = (1− ωi,1) {(1− V ES) ziciρ p (t)}
(5.3.3)
Where i = 1, ..., n2 is the subject indicator, g = 0, 1 is vaccine group indicator and
h0,i(t) and h1,i(t) are the hazard functions in the reference group and in the experi-
mental vaccine group respectively.
We consider two mechanisms of VE: complete protection for a proportion of the sub-
jects (pi0 and pi1) and partial protection for the susceptibles (V ES). Total efficacy level
is computed as 1−
{
1−pi1
1−pi0 (1− V ES)
}
(Halloran et al. 1992). The susceptibility sta-
tus, ωi,0 or ωi,1, follows a Bernoulli distribution with respectively parameter pi0 or pi1
and is equal to 0 when the subject is susceptible to the disease, 1 otherwise. We con-
sider a number of daily contacts relevant to the spread of infection for each subject.
The contact term ci is drawn from a positive distribution and bounds the cumulative
hazard of the survival part. The probability that a contact is infectious at time t is in-
troduced through the prevalence of the disease, p(t). Fragility is included as a frailty
term zi (Duchateau and Janssen 2007). Finally, the hazard is proportional to the the
transmission probability ρ of the disease.
5.3.1 Individual frailty
In our conditional model, the individual instantaneous risk of disease is multiplied by a
fragility level zi drawn from a strictly positive continuous distribution. Since the shape
of the frailty distribution does not impact the estimation of the fixed effects (Pickles
and Crouchley 1995) and following Duchateau and Janssen (2007), we propose to use
a one-parameter gamma distribution with variance parameter δ with δ > 0. We write
the Laplace transform
Lga(s) = (1 + δs)−
1
δ (5.3.4)
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and the corresponding marginal survival function is then
Smarginal(t) = L (− log(Scond(t))
= (1− δ log (Scond(t)))
− 1
δ
(5.3.5)
where Scond corresponds to the conditional survival function for z = 1. The corre-
sponding marginal hazard is
hmarginal(t) = (1− δ log (Scond(t)))−1 hcond(t) (5.3.6)
where hcond is the conditional hazard function.
We now compare the conditional (HRcond = exp(β1)) and the marginal hazard ratio
for the vaccine effect binary covariate and we derive the marginal HR
HRmarginal =
hmarginal,1(t)
hmarginal,0(t)
=
(1− δ log (S0(t)) exp(β1))−1 h0(t) exp(β1)
(1− δ log (S0(t)))−1 h0(t)
(5.3.7)
and the marginal VE
V Emarginal(t) = 1−HRmarginal
= 1−
{
(1− δ log (S0(t)))
(1− δ log (S0(t)) exp(β1)) exp(β1)
} (5.3.8)
where S0(t) is the survival function at time t in the reference group conditional on the
frailty and exp(β1) is the vaccine effect.
Marginal VE decrease with AR and the departure is directly related to the conditional
VE level and the variability of the frailty term.
Figure 5.1 A shows V E as a function of AR in the reference group for 4 levels of
leaky vaccine efficacy (0, 0.3, 0.5 and 0.7) and δ = 4. This value leads to a large het-
erogeneity in the levels of fragility at the beginning of the observation period, based
on the fact that post-vaccination immunogenicity markers, usually the disease anti-
body titres, tend to be very heterogeneous among subjects having received the same
vaccine (Thomas and Moridani 2010). Even in presence of a highly variable fragility
term, when the outcome of interest is uncommon (below 10%) and thus the cumula-
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tive hazard is low, only small departures from the initial VE are observed. The size of
the departure is positively related to the level of heterogeneity.
5.3.2 Number of daily contacts
At the individual level, contacts rate heterogeneity is introduced through a multiplica-
tive term with a positive discrete distribution. Following Mossong et al. (2008) we
draw the contact term from a negative binomial distribution with parameters φ and
η, with φ > 0 and η ≥ 0. Following Tournoud and Ecochard (2008), we write the
Laplace transform
Lnb(s) =
(
φ
φ+ η(1− exp(−s))
)φ
(5.3.9)
The corresponding survival function is then
Smarginal(t) = L (− log(Scond(t))
= exp
{
−φ log
[
1 +
η
φ
(1− Scond(t))
]} (5.3.10)
where Scond corresponds to the conditional survival function for c = 1. The corre-
sponding marginal hazard is
hmarginal(t) =
ηScond(t)hcond(t)[
1 + ηφ (1− Sc(t))
] (5.3.11)
where hcond is the conditional hazard function.
We now compare the conditional (HRcond = exp(β1)) and the marginal hazard ratios
for the vaccine effect binary covariate and we derive the marginal HR
HRmarginal =
hmarginal,1(t)
hmarginal,0(t)
= exp(β1)
φ+ η (1− S0(t))
φ+ η (1− S0(t))exp(β1)
S0(t)
exp(β1)−1
(5.3.12)
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and the marginal VE
V Emarginal(t) = 1− hmarginal,1(t)
hmarginal,0(t)
= 1−
{
exp(β1)
φ+ η [1− S0(t)]
φ+ η
[
1− (S0(t))exp(β1)
]S0(t)exp(β1)−1}
(5.3.13)
Marginal VE decreases with AR. The departure is positively related to the conditional
VE level and to the two parameters of the negative binomial contact term.
Figure 5.1 B shows V E as a function of AR in the reference group and for 4 levels
of leaky vaccine efficacy (0, 0.3, 0.5 and 0.7), for a negative binomial contact term
characterized by η = 18 and φ = 10.36 (Mossong et al. 2008). Marginal VE quickly
decrease over time and proportionally to the initial VE.
5.3.3 Vaccine mechanism of protection
When the mechanism of vaccine protection is a mixture of an all-or-none and a leaky
mechanisms, the studied population will combine both a totally and a partially im-
mune subpopulations of individuals. To consider both efficacy mechanisms, we can
use a mixture model where the overall survival of the population, Smarginal(t), is de-
composed into two components: a proportion pi (corresponding to pi0 or pi1 depending
on the vaccine group) of immune (not susceptible) subjects and a proportion 1 − pi
(corresponding to 1−pi0 or 1−pi1 depending on the vaccine group) of the population
whose time-to-event are defined by a survival function S(t). The two components of
the model are affected by the vaccine.
Following Hougaard (1999), we propose to use a Bernoulli distribution with parameter
pi for the proportion of immune subjects with 0 ≤ pi ≤ 1. Following Tournoud and
Ecochard (2008), we write the Laplace
LBe(s) = (1− pi) + pi exp(−s) (5.3.14)
and the corresponding marginal survival function is then
Smarginal = L (− log(Scond(t))
= pi + (1− pi)Scond(t)
(5.3.15)
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where Scond corresponds to the conditional survival function, i.e. the survival function
of the susceptible fraction of the population. The corresponding marginal hazard is
hmarginal(t) =
(1− pi)hcond(t)Scond(t)
pi + (1− pi)Scond(t) (5.3.16)
where hcond is the conditional hazard function.
We now compare the conditional (HRc = exp(β1)) and the marginal hazard ratios
for the vaccine effect binary covariate and we derive the marginal VE.
HRmarginal =
hmarginal,1(t)
hmarginal,0(t)
= exp(β1)
1− pi1
1− pi0
pi0 + (1− pi0)S0(t)
pi1 + (1− pi1)S0(t)exp(β1)S0(t)
exp(β1)−1
(5.3.17)
V Emarginal(t) = 1− hmarginal,1(t)
hmarginal,0(t)
= 1−
{
exp(β1)
1− pi1
1− pi0
pi0 + (1− pi0)S0(t)
pi1 + (1− pi1)S0(t)exp(β1)S0(t)
exp(β1)−1
}
(5.3.18)
where exp(β1) is the vaccine effect in the survival portion of the model, pi is the pro-
portion of subjects totally protected by the vaccine and S0(t) is the survival function
at time t in the reference group.
Marginal VE tends to increase with AR and with the relative proportion of the type II
(all-or-none) mechanism in the total conditional VE.
As an illustration, we have computed V E as a function of AR for a mixed protection
VE mechanism with pi0 = 0 (all subjects from the reference group are susceptible)
and pi1 = 0.20 and total efficacy of 0, 0.3, 0.5 and 0.7 (Figure 5.1 C).
5.4 Simulations study
When estimating VE without accounting for subject heterogeneity, we make the as-
sumption that VE is constant over time. However, we showed that the inclusion of
sources of heterogeneity resulted in time-varying marginal VE. Consequently, if the
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Figure 5.1: Marginal VE as a function of conditional VE and AR in the susceptible
reference group.
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heterogeneity is not accounted for in the analysis model, the estimated VE will actu-
ally correspond to an average efficacy over the period of observation.
5.4.1 Simulation setting
We run a large simulation study to quantify the amount of the biases resulting from
misspecified regression models. We use the conditional model described in Chapter
4 to generate clinical trial data. Because we want to include seasonal effect in our
generated data, we derive the probability that a contact is infected, p(t), from historical
data (Benoit et al. Conditionnaly accepted).
For each of the 3 scenarios described above and an additional one combining all het-
erogeneity sources, 500 trials with 10000 subjects equally allocated to the two treat-
ment groups and two countries were simulated. Prevalences p(t) were derived from
FluNet (Flahault et al. 1998) surveillance data for the German and the U.S. flu season
2000-01 for all circulating influenza strains. Our data generation algorithm allows to
capture the variations in occurrence time, magnitude of the epidemic peaks as well as
the strains repartition over time and geographical regions (Benoit et al. Conditionnaly
accepted). Transmission probability was modulated in order to reach attack rates in
the susceptible sub-population within the reference group (AR0) between 0.02 and
0.20.
VE was estimated through logistic, Poisson, Cox regression models including vaccine
and country effects. We only considered censoring due to the termination of the trial.
Median estimated VE with 95% empirical confidence intervals (percentiles 2.5 and
97.5) are presented as a function of AR0 and by conditional efficacy levels (Figure
5.2)
5.4.2 Results
When no source of heterogeneity is considered in data generation and a leaky VE
mechanism, estimations from the logistic regression are characterized by a slight VE
overestimation trend increasing with AR0. Estimates from the Poisson and the Cox
regression models are in close agreement with the true values.
When data are generated with sources of heterogeneity, the logistic regression for low
AR, the Cox and the Poisson regression lead to very similar results. Therefore, we
only present the Cox regression estimates.
We first simulate data allowing different levels of fragility of the people under study.
Our frailty term is generated from a one-parameter gamma distribution with δ = 4 as
in the previous section. In this case, VE from the misspecified Cox model slightly un-
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derestimates the true efficacy. Underestimations are more important at higher efficacy
levels and for higher baseline attack rates.
VE estimated from a misspecified Cox regression on data simulated with heterogene-
ity in the daily number of contacts gives estimates very close to the real efficacy levels
used in the simulations, although a slight trend toward underestimations can be seen
as AR0 increases.
The misspecified Cox regression very slightly overestimates VE when the vaccine
has a mixed mechanism of protection. Overestimations are visible at higher base-
line attack rates and when the all-or-none part of the protection mechanism is more
prevalent, at smaller VE levels.
When the studied sources of heterogeneity are combined, VE estimates from a mis-
specified Cox regression tend to be smaller than the simulated efficacy levels. The
bias increases both VE and baseline attack rates.
At low event rates, all models gave good VE estimates, even when sources of het-
erogeneity are omitted in the analysis model. Based on our results, it seems that,
whenever AR are low (as is expected for many infectious diseases), models taking
into account the time of exposure, such as the Poisson or the Cox model should be
preferred. More complex models should be considered only in case of larger AR.
5.5 Additional results
In the previous section, we have shown that analysis regression models not taking into
account the sources of heterogeneity gave surprisingly good estimates of the true VE
at low AR. However, if the source of heterogeneity is of particular interest or when
the expected AR are higher, one should use a more complex model. In this section,
we first discuss and present simulations results of Cox survival models including an
univariate frailty or a cure fraction. On the opposite, we explore the possibility of
estimating VE with an even more simple model, the exponential survival model. We
show that for low AR, a simple fully parametrical survival model assuming constant
hazard gives estimated VE close to the true VE values.
5.5.1 Univariate frailty
We have shown that failing to account for subject heterogeneity in the analysis of VE
data did not lead to a clinically-relevant bias when AR were low. However, if we want
to model this heterogeneity (either because of a particular interest or in the setting of
higher AR), a frailty model can be used (Duchateau and Janssen 2007). In this section,
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Figure 5.2: Estimated VE (median and estimation 95% CI) over AR0 by simulated
VE and omitted sources of heterogeneity. Dotted lines represent the true VE, solid
lines represent the median estimated VE with a 95% CI.
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Figure 5.3: VE estimates (with 95% empirical CI) obtained with a Cox regression
model univariate frailty (right) or not (left)
we compare the VE estimates from a Cox PH model model accounting for individual
heterogeneity and a a Cox PH model including an univariate frailty.
Univariate frailty models (Wienke 2010) allow to account for unobserved individual
heterogeneities. The individual hazard function with frailty z for a PH survival model
is given in equation 4.2.1 of chapter 4.
We generate data from 500 trials with sample size 10000 including an individual ran-
dom fragility generated from a one-parameter gamma distribution with δ = 4, in
order to reflect a 10-fold risk difference between the mean and the percentile 99 sub-
jects, translating large fragility differences between healthy subjects and subjects with
concomitant co-morbidities. We analyse the data using a Cox regression model that
either includes or does not include a univariate gamma frailty term. The results of
these analyses are presented in figure 5.3.
While including an univariate frailty in the analysis modelled for VE trials data im-
proves the quality of the estimates at higher AR, the assumptions made for this model
can be quite strong. The biggest problem is that in a Cox regression model, unob-
served heterogeneity cannot be distinguished from a situation of homogeneity under a
non-proportional hazards model (O’Quigley and Stare 2002). As a result, when choos-
ing to include an univariate frailty, we make the strong assumption that the underlying
cause of non-proportionality is heterogeneity and not time-varying covariate(s) ef-
fect(s), for example waning of the vaccine effect over time. Also, a distribution has to
be specified for the frailty part of the model. While it has been shown that the choice
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of the frailty distribution does not affect the estimation of the survival function param-
eters (Pickles and Crouchley 1995), misspecification of the frailty distribution might
be problematic if one is interested in the random effect.
5.5.2 Cure model
The mixture cure model has been developed by Boag (1949) and Berkson and Gage
(1952) in the context of oncology studies.. The overall survival of the population
includes two components: a proportion pi of cure subjects and a proportion (1− pi) of
the population whose time-to-event can be characterized by a survival function. In the
context of seasonal influenza VE, the cured fraction correspond to the subjects who
are not susceptible to the disease.
Mixture cure models allow to simultaneously estimate the incidence, i.e. the probabil-
ity that an event of interest will occur and the latency, i.e. when it will occur given that
it occurs (Corbière and Joly 2007). Let ω be the indicator of susceptibility, set to 1
when the subjects is non susceptible, 0 otherwise. The unconditional survival function
is given by
S(t|X1 = x1) = pi(X1 = x1)+((1− pi(X1 = x1))S(t|X1 = x1, ω = 0)) (5.5.1)
where S(t|X,ω = 0) is the survival function for the susceptible subjects and pi(X1 =
x1) is the probability of being non susceptible for a subject with vaccine group factor
x1. This probability is modelled through of binary regression model (Corbière and
Joly 2007). One of the popular models is the logistic regression model where
logit(pi(X1 = x1)) = α0 + α1x1 (5.5.2)
where α0 is the intercept and α1 the vaccine effect parameter associated with the
incidence part of the model. The survival function for the susceptible subjects is model
through a Cox regression model with β1 the vaccine effect parameter associated with
the latency part of the model.
Total VE (Halloran et al. 1996) is computed as
V Etot = 1− (exp(α1)× exp(β1)) (5.5.3)
The main issue with cure models is how to identify the subjects who are completely
protected. Indeed, when the time of follow-up is too short, making the difference
between the non susceptible subjects and the subjects who will develop the infection
82 Chapter 5. Estimation of seasonal influenza vaccine efficacy
after the closing of the study is impossible (Taylor 1995; Li et al. 2001). Simplification
assumptions have to be made. We apply the frequently used zero-tail assumption that
assumes that all non infected subjects by the end of the trial were not susceptible. As
such, we wrongly consider that all the non infected subjects were not susceptible.
We model the effect of the vaccine on the cured fraction through a logistic regression
model and the survival part of the model through a Cox regression model (Corbière
et al. 2009). We fit our model through the SAS macro PPSMCM developed by Cor-
bière and Joly (2007).
We generate data from 250 trials with sample size 10000 and include 20% of non
susceptible subjects in the group who received the experimental vaccine. Overall sim-
ulated efficacy, including a leaky and a all-or-none portions, is 70% and we generate
data with AR levels of 2% and 15%. While the latter level of AR is highly improbable
in the context of influenza, it was selected for the purpose of illustration. We anal-
yse the trials data with a logistic regression, a Cox regression and a semi-parametric
mixture cure model.
The results of our simulations are presented in figures 5.4 and 5.5. Note that Figures
5.4 and 5.5 are presented in different y-scales in order to preserve their readability. For
both AR values, VE estimates from the cure model are more variable than those from
the Cox and the logistic regression models. When the AR is greater, the estimates
from the cure model suffer from the same drawback as the estimates from the logistic
regression model, i.e. the OR are no longer a good approximation of the RR and VE
are overestimated.
5.5.3 Exponential model
Throughout this work, we have shown that in the situation where censoring is high,
incomplete parsimonious (few parameters) models tend to give good estimates of VE,
sometimes even better than more complex models. Because seasonal influenza tends
to have non-constant incidences over time, our recommendation is to apply a model
that does not make any assumption on the baseline hazard. However, since the Poisson
regression gave VE estimates very close to the true values, we decided to explore
the quality of the estimates obtained through a the exponential survival model, the
simplest possible survival distribution, which assumes a constant risk over time. The
hazard is defined as h(t) = h.
We generate data from 500 trials with sample size 10000 and including no sources
of heterogeneity. We analyse the data with a Cox regression model and with an ex-
ponential survival model. The results of these analyses are presented in Figure 5.7 A
(Cox regression model) and B (Exponential survival regression model). For illustra-
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Figure 5.4: VE estimates for a Cox, a cure and a logistic model for data generated
with a mixed vaccine protection mechanism for an AR of 2%.
Figure 5.5: VE estimates for a Cox, a cure and a logistic model for data generated
with a mixed vaccine protection mechanism for an AR of 15%.
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tion purpose, we simulate AR from 1% to 70%. Figure 5.6 shows the historical data
used to compute the daily probabilities of a contact infectiousness, pk(t), where k is
the strain indicator.
At low AR, the exponential model give results very similar to the Cox regression
model.
5.6 Discussion
It seems from a review performed in Chapter 2 that very simple models are used to
analyse Phase III VE trials. However, seasonal influenza epidemics are complex and
the use of those models is increasingly being questioned by the regulatory agencies.
In this chapter, we assess the quality of the estimates of VE obtained with the logistic,
Poisson and Cox regression models in the context of seasonal influenza VE trials.
In presence of heterogeneity and constant conditional VE over time, marginal VE
varies with time of exposure. Consequently, marginally, the hazards are no longer
proportional. The departure from the initial VE increases with AR0 and VE levels.
At low attack rates however, these departures are small. When analysing data without
taking into account heterogeneity, VE is assumed to be constant and the estimated VE
correspond to an average efficacy over the period of observation. We ran a simulation
study in the context of influenza to quantify the magnitude of the departures that could
be obtained.
VE estimates from logistic, Poisson and Cox regression models were found to be un-
biased for highly censored seasonal homogeneous data. It would be interesting to
extend our work to the analysis of trials data run over several seasons and including a
succession of periods with very low or null disease incidence and periods of high dis-
ease circulation. With higher baseline attack rates, logistic regression vaccine efficacy
estimates based on the odds ratios gave slight overestimations of the true efficacy, as
expected (Lachin 2011; Zhang and Kai 1998).
Inclusion of a non susceptible sub-population in the studys led to an overestimation
of VE while omission of heterogeneity resulted in an underestimated VE. The results
of the simulations are consistent with our analytical results, except in the case of the
contacts heterogeneity. In all cases, we showed that at high censoring levels, i.e. low
cumulative attack rates over the observation period, the bias was negligible and did
not affect the conclusions of the trial.
The effect of combining several sources of heterogeneity is more difficult to predict
based on the analytical results. Indeed, departures from the conditional VE go into op-
posite directions and have varying intensities. We therefore studied this case through
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Figure 5.6: Incidences over time of strains of influenza by country for season 2000-
2001
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Figure 5.7: VE estimates and 95% CI from a Cox regression model (left) and a fully
parametrical exponential survival regression model (right)
simulation. While VE estimates were biased (underestimated), especially with higher
AR, in situations similar to the typical influenza season, biases were negligible, with
no medically-relevant impact on the conclusions of the trials. Moreover, the estimates
tend to be conservative. Poisson and Cox regressions should be preferred to logistic
regression that can give slightly biased estimations even if correctly specified.
In the case of higher AR (over 10%), more appropriate models, such as Cox regres-
sion including a frailty term, a cure fraction, or a combination of the two, should be
preferred. In the case of the cure model, RR should be used instead of OR for the
incidence part of the model. These models however have to be interpreted carefully.
First, it is impossible to distinguish the effects of heterogeneity from the time-varying
covariate effects. For example, the inclusion of a univariate frailty might hide the
presence of vaccine waning (Moghadas 2004) or virus mutations over time (Antia
et al. 2003). Second, accurately estimating the cured (non susceptible) sub-population
requires sufficient follow-up in order to distinguish between the "cured" subjects (Hal-
loran et al. 1996; Li et al. 2001; Peng and Zhang 2008) and the susceptible subjects
who have not been infected yet.
In the next chapter, we challenge the traditional paradigm of phase III trials for VE
against seasonal influenza. We argue that the actual methodology provides an incom-
plete answer to the question of VE in the future.
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Summary of Chapter 5
• Vaccine efficacy clinical trials data are usually analysed through Cox, logistic
or Poisson regression models. However, the particularities of influenza are in
contradiction with some assumptions of those models.
• When there is latent heterogeneity at the individual level, marginal vaccine effi-
cacy over time is no longer constant.
• When the model used to estimate vaccine efficacy does not take into account
individual heterogeneity the estimated vaccine efficacy is an averaged efficacy
over the surveillance period.
• At low attack rates however, departures from the conditional vaccine efficacy
are not clinically relevant. Therefore, we recommend to keep using parsimo-
nious data analysis models such as the Poisson and the Cox regression models.
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Chapter6
Accounting for strain
heterogeneity in the estimation
of vaccine efficacy against
seasonal influenza
In this chapter, we propose a new trial design and analysis methodology that allows
the characterization of the VE heterogeneity between countries and influenza seasons
(referred as clusters). In addition, we also suggest the use of predictive intervals for
future cluster-specific VE instead of intervals for the mean VE.
We analyse trial data with a hierarchical survival model taking into account risk het-
erogeneity and VE heterogeneity across clusters. Our model parameters and the sta-
tistical intervals for the cluster-specific VE are estimated using Bayesian statistics.
We illustrate our methodology through a large simulation study and by re-analysing
the trial Influence 65. We argue that our methodology provides better insight on the
range of future VE across seasons and geographical regions.
89
90 Chapter 6. Accounting for strain heterogeneity in the estimation of VE
6.1 Introduction
Influenza is an infectious disease caused by several virus strains that present varying
repartitions between geographical regions and seasons. Typically, a vaccine contains
three or four influenza strains and the antigen content is annually reconsidered based
on the WHO recommendations. For the same vaccine formulation, pharmaceutical
regulations only require efficacy again clinical disease to be shown for a single season,
which is performed through a large phase III trial. Subsequent annual modifications
of the strain related portion of the vaccine only have to be validated through immuno-
genicity trials (see Chapter 2 for more details about the development of a vaccine).
Classically, influenza VE trials take place over a single season but over several ge-
ographical regions assuming common VE. However, depending on the circulating
strains characteristics such as their immunogenicity and their matching levels with
the vaccine strains, the vaccinal protection levels may vary from one season/region to
another. As a result, the same vaccine can sometimes be proved to be significantly
efficacious in one trial but not the other, all other things being equal.
We argue that not accounting for this provides incomplete and unreliable response
as for the benefit of the vaccine in the future. We therefore propose to run phase III
VE trials over several geographical regions and seasons in order to characterize the
VE heterogeneity. We consider VE as the sum of a common quantity to all clusters
(season and geographical region) and of a random cluster-specific part. We propose
to account for strain heterogeneity between seasons and regions by including estima-
tions of two heterogeneity terms between clusters in the analysis model. Following
(Legrand et al. 2009), we suggest the use of a Cox frailty model including two ran-
dom terms: the random effect at the baseline hazard level accounts for the varying
evolutions over time of the seasonal epidemics between clusters while the random
effect at the vaccine effect level allows to assess the heterogeneity of VE between
clusters, strains heterogeneity. This methodology is already applied in the context of
meta-analyses when aggregating individual patient time-to-event data as differences
across trials in terms of design, methodology or patients characteristics can contribute
to create variability in the treatment effect of interest (Smith et al. 2005; Higgins et al.
2009).
Classically, the primary objective of a CT is to prove that the experimental treatment
is likely to have the expected effect in the trial population. To address this objective,
confidence intervals and hypothesis tests about the mean treatment effect (FDA 2007)
are conducted. The assumption is that, if used in the same population and under the
same conditions (compliance and dosage for example), the experimental treatment
will have a similar effect once marketed. Yet, in seasonal influenza efficacy trial,
because of spacial and temporal heterogeneity, this assumption is less evident. We
argue that the objective of a phase III trial should be to prove that the vaccine will
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be efficacious in the future. We believe that in the particular context of VE against a
heterogeneous disease such as seasonal influenza the decision about VE should not be
taken based on a confidence interval for the mean estimated VE, as is actually done,
but based on predictive intervals, accounting for the heterogeneity across clusters. In-
deed, such information provides insight on the range of future VE across seasons and
geographical regions, instead of a mean past season specific vaccine effect. To derive
information about VE in the future, i.e. for new clusters, we propose to use predictive
intervals instead of confidence intervals. This methodology is routinely used in the
industrial context for example where the conformity of new objects manufactured in
batches is assessed through tolerance intervals (Wolfinger 1998).
In the Bayesian setting, all model parameters are assigned a probability distribution
(Carlin and Louis 2000). Because of this characteristic, the Bayesian algorithm is bet-
ter suited for solving problems such as computing statistical intervals and especially
tolerance intervals (Wolfinger 1998). For this reason, we chose to develop this chapter
using Bayesian inference.
In the next section, we propose a short introduction to Bayesian inference. Our sug-
gested analysis model is presented in section 6.3. Types of statistical intervals and their
uses are presented in Section 6.4. Implementation of our methodology is detailed in
section 6.5. Finally, we illustrate our methodology through a simulation study and a
re-analysis of the data from study Influence 65 in Sections 6.6 and 6.7.
6.2 An introduction to Bayesian inference
Gelman (2004) defines Bayesian inference as "the process of fitting a probability
model to a set of data and summarizing the result by a probability distribution on
the parameters of the model and on unobserved quantities such as predictions for new
observations". The posterior distribution for θ, the vector of parameters to estimate, is
written p(θ|y) and represents the uncertainty about θ conditionally to the data y (Lunn
et al. 2012). Based on Bayes’s theorem, it is expressed as:
p(θ|y) ∼ L(θ; y)p(θ) (6.2.1)
where L(θ; y) is the likelihood of the data given the parameter values and p(θ) is the
prior distribution for θ.
Prior distributions can be vague or informative. The use of vague priors is recom-
mended when one wishes to retrieve all information about the posterior distribution
of the parameters of interest from the data in hand while the use of informative priors
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acknowledges that there is prior information or intuition on the parameters of interest
(Congdon 2007).
To derive the posterior distributions of the parameters of interest, the nuisance param-
eters have to be integrated out of 6.2.1. Depending on the complexity of the model,
this can be done analytically or through numerical solutions (Lunn et al. 2012; Lebrun
2012). When numerical solutions are applied, large samples of instances for the vari-
ables to estimate are generated from the posterior joint density and the properties of
their distributions are empirically derived from the samples (Lunn et al. 2012). When
a full set of conditional posterior distributions can be identified, Gibbs sampler is the
most current sampling algorithm: it generates a multi-dimensional Markov chain by
splitting the vector of random variables θ into subvectors and sampling each vector,
one by one, given the most recent values of all the other elements of θ and the data.
When conditional posterior distributions can not be identified, Metropolis sampling
algorithms are then used.
6.3 Analysis model
We postulate that estimated VE in a CT arises from the true underlying VE and from
virus strains (and sub-strains) related information, such as the matching level between
the vaccine and the circulating strains and the strain specific VE. Because strains repar-
titions change between geographical regions and influenza seasons, further referred as
clusters, cluster-specific VE can vary (DiazGranados et al. 2012). One could argue
that VE should thus be estimated for each strain. However, because strains composi-
tion of the vaccine will change in the future, this would not address the objective of
proving that the vaccine will be efficacious for most people who will receive it in the
future.
We consider a CT including J clusters (j = 1, ...J) each including nj subjects yield-
ing to a total sample size N . Our analysis model includes two levels of heterogeneity:
at the level of the baseline risk and as a random vaccine-effect-by-cluster interaction.
We represent the effect underlying the jth of J clusters by b0,j . We consider that the
b0,j are drawn from a distribution fB0 such that E[b0] = 0 and var(b0) = φ
2. We
represent the interaction effect underlying the jth of J clusters by b1,j . We consider
that the b1,j are drawn from a distribution fB1 such that E[b1] = 0 and var(b1) = τ
2.
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We define the hazard function for the ith individual in the jth cluster as:
λij(t|J = j,X = x) = λ0(t) exp(b0j + (β1 + bij)xij) with
b0j ∼N(0, φ2)
b1j ∼N(0, τ2)
(6.3.1)
where τ2 is a measure of the heterogeneity between clusters at the VE level and φ2
of the heterogeneity between clusters at the baseline risk level. We can also write
λ0j = λ0(t) exp(b0j).
6.4 Statistical intervals
Different types of statistical intervals can be built based on the estimations obtained
from our proposed analysis model. The type of interval to be computed will strongly
depend on the underlying problem or application (Krishnamoorthy and Mathew 2009).
Intervals are given different interpretations in the Bayesian and the frequentist set-
tings. The frequentist approach regards the model parameters as fixed unknown quan-
tities. In this approach, a statistical interval is interpreted as a range of values that are
believed to likely contain the true parameter value (Hahn and Meeker 2011). More
precisely, it is interpreted as a range in which the parameter of interest would occur
100(1 − α)% of the time with repeated sampling. Bayesians treat model parameters
as unknown random quantities and described them probabilistically. They interpret
intervals as the region of values, denoted [L,U ], that contains 100(1 − α)% of the
posterior probability of the parameter of interest such that
∫ U
L
p(θ|y)dθ = 1− α (6.4.1)
Following this methodology, intervals can be similarly derived for a function of the
model parameter(s).
For a parameter θ, the highest posterior density (HPD) interval is the shortest interval
containing 100(1− α)% of the posterior sample for θ while the equal-tail is obtained
using the empirical percentiles of the posterior distribution of θ. This latter interval
definition has been privileged in this chapter.
In this section, we give the definition of each type of interval used in our work. Prac-
tical computation of the intervals will later be presented in section 6.5.
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Credible intervals
Conventionally, significant VE is statistically showed when the lower bound of the
two-sided 95% confidence interval of VE is substantially above zero (CDC 2011) (see
Chapter 2 for more details).
A credible interval is the Bayesian analogue of a confidence interval in the frequentist
setting.
As shown by Higgins et al. (2009), the presentation of inference only for the mean
VE provides an incomplete summary and is highly misleading when there is hetero-
geneity. In a context such as seasonal influenza where VE includes a cluster-specific
component, a credible interval for the trial mean VE does not address the question of
the protection of subjects from new clusters (new season and/or new country).
A one-sided interval for the parameter of interest β1 can be defined as the interval
[L(β1),+∞[ (lower bound) or ]−∞, U(β1)] (upper bound) containing 100(1−α)%
of the posterior density of β1. Once the posterior distribution of β1 is known, the
problem reduces to the computation of L(β1|y) or U(β1|y) that satisfies
P (β1 ≥ L(β1|y)) = 1− α
or
P (β1 ≤ U(β1|y)) = 1− α
In the Bayesian setting, a 100(1−α)% credible interval for β1 is a subset ofB1, where
B1 is the set of possible values for β1, such that:
∫ +∞
L
p(β1|y)dβ1 = 1− α
or ∫ U
−∞
p(β1|y)dβ1 = 1− α
The posterior density of β1, denoted p(β1|y) can be derived by averaging the joint
posterior density of the model over the nuisance parameters. When this integral has
no analytic form, it can be evaluated numerically.
An equal-tail two-sided interval for β1 can be defined as the interval [L(β1), U(β1)]
containing 100(1−α)% of the posterior density of β1. Once the posterior distribution
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of β1 is known, the problem reduces to the computation of L(β1|y) and U(β1|y) that
satisfies
P (β1 ≥ L(β1|y)) = 1− α
2
and
P (β1 ≤ U(β1|y)) = 1− α
2
In the Bayesian setting, a 100(1 − α)% credible interval for for β1 is a subset of B1
such that:
∫ U
L
p(β1|y)dβ1 = 1− α
Prediction intervals
To derive information about a new random effect, we can compute a prediction inter-
val for the random effect of interest, denoted β1,new. Heterogeneity around the mean
effect β1 is accounted for in the computation of the prediction interval for a new ran-
dom effect. This interval does also consider the uncertainty of the parameter estimates,
that is the imprecision in the estimations of the mean effect β1 and the variance of the
random effect, τ2. Senn (2004) suggests that such an interval provides a reasonable
prediction for a randomly chosen future unit, here a cluster.
We define a new random effect as β1,new = (β1 + b1|y). A one-sided interval
for β1,new can be defined as the interval [L(β1,new),+∞[ (lower bound) or ] −
∞, U(β1,new)] (upper bound) containing 100(1 − α)% of the posterior density of
β1,new. Once the posterior distribution of β1,new is known, the problem reduces to
the computation of L(β1,new|y) or U(β1,new|y) that satisfies
P (β1,new ≥ L(β1,new|y)) = 1− α
or
P (β1,new ≤ U(β1,new|y)) = 1− α
A 100(1− α)% prediction interval for β1,new is a subset of B1 such that:
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∫ +∞
L
p(β1,new|y)dβ1,new = 1− α
or ∫ U
−∞
p(β1,new|y)dβ1,new = 1− α
A two-sided prediction interval for a new random effect, β1,new, can be defined as the
interval [L(β1,new), U(β1,new)] containing 100(1 − α)% of the posterior density of
β1,new. Once the posterior distribution of β1,new is known, the problem reduces to
the computation of L(β1,new|y) and U(β1,new|y) that satisfies
P (β1,new ≥ L(β1,new|y)) = 1− α
2
and
P (β1,new ≤ U(β1,new|y)) = 1− α
2
In the Bayesian setting, a 100(1−α)% prediction interval is a subset of B1 such that:
∫ U
L
p(β1,new|y)dβ1,new = 1− α
Tolerance intervals
Prediction and tolerance intervals are closely related (Krishnamoorthy and Mathew
2009). Indeed, 100(1−α)% level p-content tolerance intervals are prediction intervals
for a fixed proportion p of new random effects. Statistically, a p-content tolerance
interval is a prediction interval for specific quantiles of the posterior distribution of
a new cluster-specific VE. Analytically deriving these quantities is very complex and
numerical solutions are often preferred.
A one-sided p-content tolerance interval is an interval on the distribution of a quantile
of the distribution of the random new random effect, β1,new. We require a 100(1−α)%
upper or lower confidence limit for gp(θ), the p quantile of β1,new, based on the pos-
terior distribution p(gp(β1,new)|y). Once the posterior distribution of gp(β1,new) is
known, the problem reduces to the computation ofL(gp(β1,new)|y) orU(gp(β1,new)|y)
that satisfies
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P (gq(β1,new) ≥ L(gq(β1,new)|y) = 1− α
or
P (gq(β1,new) ≤ U(gq(β1,new)|y) = 1− α
In the Bayesian setting, a 100(1− α)% p-content tolerance interval is a subset of B1
such that:
∫ +∞
L
p(gp(β1,new|y))dgp(β1,new) = 1− α
and ∫ U
−∞
p(gp(β1,new|y))dgp(β1,new) = 1− α
The computation of a two-sided p-content α-level tolerance interval does not reduce to
the combination of separately computed upper and lower limits of two quantiles of the
distribution of the new random effect, β1,new. Except for very simple models, numer-
ical solutions are usually necessary to compute tolerance intervals (Krishnamoorthy
and Mathew 2009).
Wolfinger (1998) developed the following methodology: bivariate pairs of g 1−p
2
(β1,new)
and g 1+p
2
(β1,new) are computed from the joint posterior density, forming a sample of
size S from the bivariate posterior density of the 1−p2 and
1+p
2 quantiles. A two-
sided tolerance interval symmetric about the posterior mean is then built by iteratively
searching an interval centered around the posterior mean and containing 100(1−α)%
of the (g 1−p
2
(βs1,new), g 1+p
2
(βs1,new)) bivariate pairs, with s = 1, ..., S.
6.5 Implementation of the methodology
In this section, we present the practical implementation of our methodology. We first
talk about the model parameters estimation. Then, we present a methodology to derive
the credible, prediction and p-content tolerance intervals when no analytical solutions
exist.
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6.5.1 Model estimation
For simplicity and based on results from Chapter 5, we present the case of a com-
pletely parametric model in which time-to-event are coming from an exponential dis-
tribution, assuming a constant hazard over time, λ0(t) = λ0 = exp(β0).
To improve the convergence of our model estimation, we apply a hierarchical center-
ing re-parametrization, that is, we assume individual models centered around a popula-
tion model (Gelfand et al. 1995). b0 and b1 are assumed to follow normal distributions
centered in β0 and β1 respectively. This re-parametrization leads to slight notation
changes. From now on, vaccine effect in a new cluster corresponds to b1,new. Our
model has the form:
λij = exp((b0j) + (b1jxij)) (6.5.1)
With j = 1, ...J and i = 1, ...nj , b0j ∼ N(β0, φ2) and b1j ∼ N(β1, τ2).
For right censored data, the information for subject i from cluster j is contained in the
pair (yij , δij) where yij is the minimum between the event time tij and the censoring
time cij . δij is the censoring indicator, taking the value 1 if the subjects were infected
with influenza during the surveillance period, 0 otherwise.
The likelihood of model 6.2.1 is given by:
L(y|β0, β1, b0, b1, φ, τ) =
c∏
j=1
nj∏
i=1
λij(yij)
δij exp (−λij(yij)yij) (6.5.2)
and the log-likelihood:
`(y|β0, β1, b0, b1, φ, τ) =
c∑
j=1
nj∑
i=1
δij log (λij(yij))− λij(yij)yij (6.5.3)
in which b0 and b1 are vectors.
We consider the following standard priors (Smith et al. 1995; Wolfinger 1998):
β0 ∼ N(0, σ2β0)
β1 ∼ N(0, σ2β1)
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and hyperpriors:
1
φ2
∼ Γ(k0, l0)
1
τ2
∼ Γ(k1, l1)
6.5.2 Intervals computation
In section 6.4, we saw that in the Bayesian setting, credible, prediction and toler-
ance intervals were derived from the posterior density of the parameter of interest, the
mean vaccine effect, β1, for credible intervals, a new cluster-specific effect, for pre-
diction intervals and quantiles of the distribution of new cluster-specific effects for tol-
erance intervals. These posterior densities can either be derived analytically from the
joint posterior density p(β0, β1, φ, τ |y) or, when no analytical solutions exist, through
MCMC simulation methodologies.
The joint posterior density function for the our model is
p(β0, β1, φ, τ |y) ∝
J∏
j=1
nj∏
i=1
[exp(b0,j + b1,jxi) exp(− exp(b0,j + b1,jxi)yi)]
×
J∏
j=1
[[
1
φ2
exp
−(b0,j − β0)2
2φ2
] [
1
τ2
exp
−(b1,j − β1)2
2τ2
]]
×
[
exp(
−β20
2σ2β0
)
][
exp(
−β21
2σ2β1
)
]
×
[
lk00
Γ(k0)
φ−2(k0+1) exp(
−l0
φ2
)
][
lk11
Γ(k1)
τ−2(k1+1) exp(
−l1
τ2
)
]
(6.5.4)
where σ2β0 is the variance for the parameter β1, σ
2
β0
the variance for the parameter
β1, k0 and l0 are respectively the shape and scale parameters of the inverse gamma
distribution for φ2 and k1 and l1 the shape and scale parameters of the inverse gamma
distribution for τ2.
The posterior density of b1 can be obtained as:
p(b1|β1, τ, y) = p(b1|β1, τ)p(β1, τ |y)
= p(b1|β1, τ)
∫
β0,φ
p(β0, β1, φ, τ |y)dβ0dφ
(6.5.5)
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In Appendix 6.A, we show that there is no analytical solution to integrate out β0 out
of the joint posterior density for an exponential survival model with no random effect.
A fortiori, the same conclusion holds for our model including two random effects.
Consequently, instead of relying on complex approximations, MCMC simulations are
used to obtain samples from the joint posterior distribution of the parameters.
Credible intervals
To make inference for β1, we draw a sample of size S of instances of the variable β1,
denoted {β1}(S). We then take the empirical (α2 )100% and (1− α2 )100% percentiles
of the posterior sample {β1}(S) for a 100(1 − α)% bilateral interval. To compute
an unilateral interval, we take the 100(1 − α)% percentile of the posterior sample
{β1}(S).
Prediction intervals
Since we do not have a closed form for the posterior distribution of β1, difficulties
also arises in the analytical identification of the predictive distribution of b1. Instead,
we apply a simple simulation procedure to draw samples from p(b1,new|y). Following
the model, the random effect b1 is distributed as a Normal with a posteriori location
(β1|y) and variance (τ2|y). We start by drawing samples of size S of β1 and τ2,
denoted {β1}(S) and {τ}2(S) respectively. We then draw a sample {b1}(S) of new
cluster-specific random vaccine effects from N(β(s)1 , τ
(s)) with s = 1, ..., S. The
prediction interval is derived by taking the empirical quantiles of this sample.
Tolerance intervals
Derivations of unilateral and bilateral tolerance intervals differ slightly so we present
them separately. In both cases, derivation of tolerance interval bound(s) start with the
generation of posterior samples for β1 and τ2 as for prediction intervals.
In the case of an unilateral tolerance interval, for each pair of β(s)1 and τ
2(s), s =
1, ..., S, a (1 − p)th quantile is derived for the bivariate samples of distributions
N(β
(s)
1 , τ
2(s)), s = 1, ..., S for a new cluster-specific vaccine effect. This sample can
be viewed as a sample from the marginal posterior of q, the (1 − p)th quantile of the
distribution of a new cluster-specific vaccine effect and inference about the posterior
distribution of this quantile can be empirically done based on this sample (Wolfinger
1998).
Construction of a bilateral tolerance interval is more complex. Indeed, we cannot
simply compute upper and lower posterior bounds separately and then combine them
since the two quantiles do not have a posterior correlation of 1 (Wolfinger 1998).
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Figure 6.1: Densities of the cluster-specific VE for τ2 = 0.04 and τ2 = 0.5 with
quantiles 5% and 95%. The dashed line indicates VE=0 (no efficacy).
Instead, we conjointly compute the ( 1−p2 )
th and p2
th quantiles from N(β(s)1 , τ
2(s)),
s = 1, ..., S. This bivariate sample, denoted {(ql, qu)}(S) can be viewed as a sample
from the marginal posterior of (ql, qu), the (1 − p)th credible interval for b1,new, a
new cluster-specific vaccine effect. We then iteratively search for the smallest interval,
symmetrical to the mean empirical vaccine effect βˆ1 and including 100(1 − α)% of
the p% posterior intervals derived in the previous step.
6.6 Simulation study
We now run a large simulation study to illustrate and explore the performances of our
proposed methodology. We generate CT data with either J = 5, 10 or 20 clusters in
combination with nj = 10, 50 or 100, yielding to total sample size between 50 and
2000. We simulate 250 datasets for each scenario.
Time-to-event observations, yij are generated from an exponential survival model with
β0 = 1 and β1 = −0.69 corresponding to V E = 0.5. We do not consider any
censoring so δij = 1 for all observations.
The cluster-specific random variables were generated as follow:
b0j ∼ N(0, φ2) with φ2 = 0.5
b1j ∼ N(0, τ2) with τ2 = 0.04 or 0.5
The smaller simulated value for τ2 was derived from trial Influence 65 while the larger
one was chosen to study the impact of large heterogeneity on the analysis results.
Figure 6.1 shows the range of cluster-specific VE generated from the two selected
distributions.
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We implemented our methodology in SAS v9.3 and used the Bayesian procedure
PROC MCMC to estimate the model parameters.
SAS code for our model
PROC MCMC data=data;
/* initial values */
PARMS beta0 0 beta1 0;
PARMS phi2 1 tau2 1;
/* Random terms definition */
RANDOM b0 ∼ normal(mean=beta0, var = phi2)
subject=cluster;
RANDOM b1 ∼ normal(mean=beta1, var = tau2)
subject=cluster;
/* Priors */
PRIORS beta0 ∼ normal(mean , var);
PRIORS beta1 ∼ normal(mean , var);
/* Hyperpriors */
HYPERPRIOR phi2 ∼ igamma(shape, scale);
HYPERPRIOR tau2 ∼ igamma(shape, scale);
/* Model definition */
linpred = ((b0)+(b1)*vaccine);
llike = event*(linpred) - time*exp(linpred);
model general(llike);
RUN;
We used the following vague priors:
β0 ∼ N(0, 0.00001)
β1 ∼ N(0, 0.00001)
1
φ2
∼ Γ(0.0001, 0.0001)
1
τ2
∼ Γ(0.0001, 0.0001)
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We compute bilateral and unilateral credibility, prediction and 80%-content tolerance
intervals. All intervals are computed at the 95% level (α = 0.05). More specifically,
the tolerance intervals are computed at the 95% level for a content of 80% of future
cluster-specific vaccine effects. We generate posterior sample of size S = 40000 with
a thinning factor of 10. Validation of the of the statistical intervals are computed as
the coverage of each interval for 10000 new β1,new values drawn from N(β1, τ2).
6.6.1 Results
The results of the simulation study are shown in table 6.1. The empirical mean, stan-
dard deviation and median for the posterior samples of the parameters of interest are
derived. The estimation of the vaccine effect fixed parameter β1 is close to the true
value in all settings. Its precision increases with the number of events by clusters and
also the number of clusters. Precision is lower when the inter-cluster heterogeneity is
larger. The estimations of τ2, as reflected by the empirical median seems to be well
estimated. Empirical mean of τ2 tends to be higher than the simulated value for de-
signs with few clusters and subjects, due to the asymmetry of this parameter posterior
distribution (Agresti and Finlay 2008).
Figure 6.2 shows the bilateral credibility, prediction and 80%-content tolerance inter-
val limits for each combination of j and nj for τ2 = 0.04. Results for τ2 = 0.5
are similar and not presented. Lower limits of the intervals for VE are presented on
the x-axis and upper limits on the y-axis. As expected, p-content tolerance intervals
are larger than prediction intervals, which are larger than credibility intervals for the
marginal VE. The length of the intervals all decreases with the number of clusters
and events. However, the gain of adding clusters seems to be greater than the gain of
adding events by cluster. For example, intervals are much smaller with J = 20 and
nj = 20 (N = 400) than for J = 5 and nj = 100 (N = 500) leading to higher levels
of significativity defined as the lower bound of the interval greater than zero.
Table 6.2 shows the mean coverages and proportions of intervals having coverage of
at least 80% for 10000 new values of b1,j . Figure 6.3 shows the mean coverages
(left column) and the proportions of validation samples for which the coverage is at
least 80% (right column) by number of clusters, number of subjects by clusters and
between clusters vaccine effect heterogeneity levels for the bilateral three types of in-
tervals. Credible intervals are not addressing the question of future cluster-specific
VE and as such no specific level of coverage for future vaccine effects is expected. In
our work, the prediction intervals address the question of the location of one future
vaccine cluster-specific effect. The mean coverages are expected to reach at least the
nominal confidence level, here 95%. Finally, p-content α-level tolerance intervals are
addressing the question of the location of p% new cluster-specific vaccine effects. The
proportion of validation samples covered in at least 80% of the cases should be at least
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95% in our setting. As expected, coverages of tolerance intervals are larger than cov-
erages of prediction intervals, which are larger than coverages of credibility intervals.
In some scenarios, coverages of the prediction and tolerance intervals, especially in
the unilateral case, are a little smaller than expected, due to Monte-Carlo sampling
errors (Lunn et al. 2012). Coverages of the credibility intervals on the mean VE, the
classical methodology, decrease rapidly as the number of events and clusters increase.
For example, for J = 10, nj = 100 and τ2 = 0.04, a situation similar to that of trial
Influence 65, a bilateral credibility intervals only covers 2% of new VE.
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Figure 6.2: Lower and upper bivariate limits and proportions of intervals excluding
VE=0 for the three types of intervals for each combination of J and nj for τ2 = 0.04.
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τ2 n by Interval J = 5 J = 10 J = 20
cluster type mean cov (≥ 0.8) mean cov (≥ 0.8) mean cov (≥ 0.8)
0.04 10 CI (bi) 0.92 (0.87) 0.81 (0.69) 0.67 (0.06)
CI (uni) 0.9 (0.83) 0.86 (0.75) 0.79 (0.58)
PI (bi) 0.99 (1) 0.97 (0.99) 0.95 (0.97)
PI (uni) 0.98 (0.97) 0.96 (0.96) 0.94 (0.94)
TI (bi) 1 (1) 1 (1) 0.99 (1)
TI (uni) 0.99 (1) 0.98 (0.99) 0.96 (0.97)
20 CI (bi) 0.85 (0.78) 0.72 (0.21) 0.56 (0)
CI (uni) 0.88 (0.79) 0.81 (0.63) 0.73 (0.34)
PI (bi) 0.98 (0.97) 0.96 (0.97) 0.92 (0.89)
PI (uni) 0.96 (0.96) 0.95 (0.94) 0.92 (0.88)
TI (bi) 0.99 (0.99) 0.99 (1) 0.97 (0.99)
TI (uni) 0.98 (0.98) 0.97 (0.98) 0.93 (0.92)
100 CI (bi) 0.75 (0.42) 0.53 (0) 0.4 (0)
CI (uni) 0.82 (0.64) 0.71 (0.28) 0.67 (0.11)
PI (bi) 0.96 (0.94) 0.92 (0.88) 0.93 (0.92)
PI (uni) 0.95 (0.95) 0.92 (0.89) 0.94 (0.97)
TI (bi) 0.99 (1) 0.96 (0.95) 0.95 (0.97)
TI (uni) 0.97 (0.97) 0.92 (0.9) 0.91 (0.96)
0.50 10 CI (bi) 0.68 (0.33) 0.54 (0) 0.4 (0)
CI (uni) 0.8 (0.59) 0.71 (0.29) 0.67 (0.1)
PI (bi) 0.9 (0.76) 0.91 (0.86) 0.94 (0.94)
PI (uni) 0.92 (0.85) 0.91 (0.88) 0.95 (0.99)
TI (bi) 0.96 (0.96) 0.95 (0.92) 0.95 (0.97)
TI (uni) 0.94 (0.91) 0.92 (0.9) 0.92 (0.96)
20 CI (bi) 0.69 (0.37) 0.51 (0.01) 0.37 (0)
CI (uni) 0.78 (0.56) 0.71 (0.26) 0.65 (0.04)
PI (bi) 0.91 (0.82) 0.93 (0.91) 0.94 (0.97)
PI (uni) 0.92 (0.86) 0.94 (0.93) 0.94 (0.98)
TI (bi) 0.96 (0.91) 0.96 (0.94) 0.94 (0.97)
TI (uni) 0.94 (0.9) 0.93 (0.94) 0.9 (0.94)
100 CI (bi) 0.68 (0.32) 0.5 (0) 0.35 (0)
CI (uni) 0.79 (0.56) 0.71 (0.2) 0.64 (0)
PI (bi) 0.94 (0.9) 0.95 (0.96) 0.94 (0.99)
PI (uni) 0.95 (0.93) 0.95 (0.98) 0.95 (1)
TI (bi) 0.98 (0.97) 0.97 (0.98) 0.94 (0.99)
TI (uni) 0.96 (0.94) 0.93 (0.96) 0.9 (0.96)
Table 6.2: Mean coverages and proportions of intervals covering at least 80% of 10000
new cluster-specific VE.
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Figure 6.3: Mean coverages and proportions of intervals covering at least 80% of
10000 new cluster-specific VE by bilateral type of interval, for each combination of j
and nj for τ2 = 0.04 and τ2 = 0.5.
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6.7 Reanalysis of trial Influence 65
In this section, we re-analyse the trial Influence 65 according to the proposed method-
ology. The conclusion of this trial was that there was no evidence of increased VE
of the adjuvanted vaccine over the standard vaccine when considering all influenza
strains (see Chapter 4 for more details), resulting in little heterogeneity across country-
specific VE. However, the efficacy results for the flu strain A/H3N2 seem more en-
couraging. For this reason, we decided to only consider the clinical influenza cases
caused by strain H3N2 for our reanalysis. VE heterogeneity across countries here
could be caused by virus mutations or varying levels of vaccine coverage for example.
We performed two analyses considering two levels of clustering: countries (J = 15)
and, for the purpose of illustration, also considered a somewhat more artificial clus-
tering into geographical regions (J = 4). We analyse the data with the model given in
equation 6.5.1 and we use standard vague priors as described in section 6.5.1. We de-
rive unilateral and bilateral 100(1− α)% level credible intervals, PI and 80% content
TI.
Model estimates for both clustering scenarios are presented in table 6.3. For the same
total number of events, estimations are much more precise in the by-country setting.
Figure 6.4 and 6.5 show the cluster-specific VE (with 95% credible interval) as well
as a 95% bilateral credible interval for the marginal VE, 95% bilateral prediction in-
terval for a new cluster-specific VE and a 80% content 95% confidence level tolerance
interval. The additional precision on both the estimations of β1 and τ2 for the analysis
considering country clustering translates into much smaller statistical intervals, espe-
cially for the prediction interval and the tolerance interval which include imprecision
information also on τ2.
Geographical region Country
Parameter Mean (sd) Median Mean (sd) Median
β0 -10.48 (1.21) -10.41 -9.9 (0.3) -9.88
β1 -0.39 (0.55) -0.32 -0.26 (0.11) -0.25
τ2 0.72 (6.74) 0.05 0.04 (0.06) 0.03
φ2 5.25 (13.18) 2.29 1.15 (0.58) 1.04
Table 6.3: Empirical means, standard deviations and medians of the model parameters
posterior samples for the reanalysis of trial Influence 65 for the geographical regions
and the countries clustering levels.
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Marginal Credible Prediction 80 % Tolerance
Cluster VE interval interval interval
Region 0.32 -0.09, 0.71 -0.74, 0.88 -3.86, 0.91
Country 0.23 0.05, 0.3 -0.21, 0.54 -0.38, 0.57
Table 6.4: 95% credible intervals for the marginal VE, prediction interval for a new
cluster-specific VE and 80% content tolerance interval for new cluster-specific VE for
the reanalysis of trial Influence 65 and by clustering level (Geographical regions or
countries).
Figure 6.4: VE by geographical region (with 95% credible intervals), marginal VE
(with 95% credible interval), 95% prediction interval for a new cluster-specific VE
and 80%-content 95% tolerance interval for new cluster-specific VE. The dashed line
represents VE=0.
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Figure 6.5: VE by country (with 95% credible intervals), marginal VE (with 95%
credible interval), 95% prediction interval for a new cluster-specific VE and 80%-
content 95% tolerance interval for new cluster-specific VE. The dashed line represents
VE=0.
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The reanalysis of the trial Influence 65 provides us with information about the VE
heterogeneity and about the VE of the adjuvanted vaccine compared to the standard of
care in the future. While the credible interval for the marginal VE gives information
about the mean VE observed in the trial, the 95% level prediction interval constructed
from the country clustering model indicates that if, for example, we were to run a
new trial within one new cluster, the new VE would be between −0.21 and 0.54,
with confidence level 95%. The 80%-content tolerance 95% level tolerance intervals
indicates that if we were to use the product in 10 new clusters, 8 of the cluster-specific
VE would be between −0.38 and 0.57, with confidence level 95%.
While predictive intervals are larger than credible intervals for the marginal mean, as
shown by the comparison of the coverages for new cluster-specific VE by the three
types of intervals in the previous section,they also provide a much more complete
answer to the question of VE in new clusters, i.e. regions and season and thus directly
address the objectives of a phase III seasonal influenza VE trial.
6.8 Discussion
Classically, seasonal influenza CT data are analysed with a model assuming constant
vaccine effect between clusters (countries and flu seasons) and decisions on the effi-
cacy of the tested vaccine are based on confidence intervals for this overall efficacy.
In this chapter, we argue that this methodology does not address the efficacy of the
tested vaccine in the future, i.e. in new clusters.
We propose an analysis model accounting for VE heterogeneity for seasonal influenza.
In combination with our model, we suggest the use of predictive intervals instead of
confidence intervals for a mean VE. Indeed, the coverage of a CI for new cluster-
specific VE is very low for design and heterogeneity levels expected in phase III trials.
This alone could explain why the same product could not be proved efficacious in one
trial and then show significant efficacy in a new trial (Beran et al. 2009b,a).
In this chapter, we have explored the use of prediction and p-content tolerance inter-
vals. While the first one gives information about the probable location of one new
cluster-specific VE, the second gives information about the location of simultaneous
p% of new cluster-specific VE. Because the seasonal influenza vaccine is expected to
be used in numerous new clusters, p-content tolerance intervals are more adapted.
Predictive intervals are larger than confidence intervals. Their lengths depends upon
the quantity of information about the mean VE, the heterogeneity between clusters,
and the information about this heterogeneity, i.e. the number of events and the num-
ber of clusters. We showed that increasing the number of clusters provided more
information (thus more precision in the estimation of the model parameters) than in-
creasing the size of the clusters. Our recommendation is to run new trials in multiple
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countries and over several seasons to collect sufficient information to have a precise
estimation of the inter-cluster heterogeneity.
While our methodology provides a better answer to question of future VE, for a similar
success criteria definition, the disadvantage is an increase of the trial size. Determi-
nation of the design and size of trials to be analysed with our methodology requires
further research. From Equation 6.5.4 and based on our simulations results, it ap-
pears that both the number of events and the number of clusters have to be taken into
account in this process. Ideas from the work realized in the context of variance com-
ponent linear models, such as Hugo (2012) and Lebrun (2012), may be helpful in this
regards. Because predictive intervals address different questions than the classically
used confidence intervals, success criteria for a trial may be modified. This particular
point should be discussed with the pharmaceutical authorities.
Our proposal also bring some interesting prospects from an exploratory point of view.
For example, by studying the heterogeneity of VE between countries, the impacts of
factors such as vaccination policies, people influenza vaccine history or the effects of
non influenza immunizations on VE could be explored.
Before application to a new phase III trial however, more research is necessary. While
our methodology can be applied in various contexts and in conjunction with differ-
ent analysis models, we made a number of simplifications for the validation part of
our work. First, we have considered the special case of no censoring and balanced
repartition of events across clusters. This assumption is highly unlikely in the con-
text of seasonal influenza phase III trials and should be relaxed in future validation
research. However, the results should not be impacted. Second, our analysis model
is a completely parametrical survival regression model which does not reflect some
of the specificities of seasonal influenza. Our methodology should be validated us-
ing more complex models such as semi-parametrical Cox regression mixed models
(Çetinyürek Yavuz and Lambert 2011; Corbière et al. 2009) or piecewise-constant
hazard frailty models (Rondeau et al. 2006). These kind of models present a new
complexity since they add source of randomness at the baseline hazard level, with
also a cluster-specific attribute. Nevertheless, because the AR of seasonal influenza
tends to be small, for sample sizes similar to what is currently done, the data tend to
be highly censored and fitting of complex model tends to be challenging.
In our work, we considered different clustering levels, as illustrated in the reanalysis
of trial Influence 65: geographical region and country. We have shown that, for the
same number of events, there was a statistical gain in having more clusters. However,
we feel that the definition of the clustering level should not be a statistical decision
but that it should be defined a priori to reflect what is clinically relevant. Influenza
geographical regions could for example be used. In our work, we have considered
geographical (country or geographical region) at the same level as season. This as-
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sumption should be explored in the future and future trials ran over several influenza
seasons.
Finally, we have used non informative priors. It could be reasonable to take advan-
tage of the Bayesian setting to include a priori knowledge about VE heterogeneity
into the analysis of phase III clinical trials. Including prior knowledge in the model
could lead to shorter intervals and potentially smaller sample sizes to reach a similar
power level as compared to the case of non-informative priors. Unfortunately, there is
little information available so far, especially about the season effect since trials tend
to be run over a single season. Whether informative priors could be retrieved from
immunogenicity trials, which are run every season, could be explored.
Summary of Chapter 6
• Because of strains heterogeneity, the classical decision paradigm for phase III
trials provides an incomplete picture of vaccine efficacy in the future.
• Our new methodology allows the characterisation of vaccine efficacy hetero-
geneity across clusters by including a random vaccine-by-cluster interaction ef-
fect.
• The use of predictive (prediction or tolerance) intervals instead of confidence
intervals to answer the question of future VE provide insight on the range of
future VE across seasons and geographical regions and is much more relevant
in the case of heterogeneous diseases.
6.A. Analytical derivations of the marginal posterior density for β1 115
6.A Analytical derivations of the marginal pos-
terior density for β1
We consider a completely parametrical model in which the survival times y follow
an exponential distribution with parameter λ0. This model implies that the baseline
hazard λ0 is constant over time. We have:
h(t|X = x) = λ0 exp(β1x) ∀ t ∈ [0,+∞[ (6.A.1)
with t ∼ exp(λ0) and h0(t) = λ0.
We re-parametrize this model as
h(t|X = x) = exp(β0 + β1x) ∀ t ∈ [0,+∞[ (6.A.2)
where λ0 = exp(β0).
This model has the following survival function:
S(t|X = x) = exp [− exp(β0 + β1x)t] (6.A.3)
The likelihood function is
L(yi; θ) =
n∏
i=1
exp(β0 + β1xi) exp(− exp(β0 + β1xi)yi) (6.A.4)
We let the two unknown parameters β0 and β1 take on the following normal prior
distributions:
β0 ∼ N(0, σ2β0)
β1 ∼ N(0, σ2β1)
(6.A.5)
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Bayesian inference is based on the posterior distribution which is obtained by multi-
plying the likelihood function with the prior density functions as given below:
pi(β0, β1|y)
∝
n∏
i=1
[exp(β0 + β1x) exp(− exp(β0 + β1xi)yi)] exp(−β
2
0
2σ2β0
) exp(
−β21
2σ2β1
)
∝ exp
[
nβ0 + β1
n∑
i=1
xi
]
exp
[
− exp(β0)
n∑
i=1
exp(β1xi)yi
]
exp(
−β20
2σ2β0
) exp(
−β21
2σ2β1
)
(6.A.6)
We seek to determine the posterior marginal distribution for β1. For that, we integrate
out the nuisance parameter β0
+∞∫
−∞
pi(β0, β1|y)dβ0 = exp
[
β1
n∑
i=1
xi − β
2
1
2σ2β1
]
×
+∞∫
−∞
{
exp
[
nβ0 − exp(β0)
n∑
i=1
(exp(β1xi)yi)− β
2
0
2σ2β0
]}
dβ0
(6.A.7)
The following integral has to be solved:
+∞∫
−∞
pi(β0, β1|y)dβ0
=
+∞∫
−∞
{
exp
[
nβ0 − β
2
0
2σ2β0
− exp(β0)
n∑
i=1
(exp(β1xi)yi)
]}
dβ0
=
+∞∫
−∞
{
exp
[
− 1
2σ2β0
(
β20 − 2σ2β0β0
(
n− exp(β0)
β0
n∑
i=1
(exp(β1xi)yi)
))]}
dβ0
(6.A.8)
Unfortunately, there is no analytical solution for this equation and the posterior marginal
distribution of β1 has to be derived through numerical methodologies.
Chapter7
Conclusion
*
Concluding discussion
Influenza is an infectious disease which seasonal epidemics cause an estimated 250000
to 500000 deaths yearly (WHO 2012). Annual vaccination is therefore recommended,
especially in the high risk populations. Unfortunately, immunosenescence and mis-
matching between vaccine and circulating strains are linked to decrease VE. To over-
come these issues, pharmaceutical companies are developing novel seasonal influenza
vaccines that offer better protection. The start point of this thesis is the observation
that many seasonal influenza phase III large clinical trials failed to show significant
VE (Dewé et al. 2013). Moreover, it also occurred that the same vaccine could not be
proved efficacious in a first trial but then showed significant efficacy, according to the
classical estimation and design methodology, in a later trial (Beran et al. 2009a,b).
Our project had two main objectives: the first objective was to understand the particu-
larities of seasonal influenza and the context in which VE trials took place. The second
objective was to use this information to improve the design of future efficacy trials, to
propose a new way of thinking the design of future efficacy trials and to propose more
appropriate statistical tools for the analyses of such trials.
We answered these objectives from different axes. In Chapter 2, we attempted to have
a better understanding of seasonal influenza and vaccination against this infectious
disease. For that, we reviewed over 100 trials. We then identified several potential
issues that we explored in the subsequent chapters.
The relevance of post-vaccination HI titres as a COP for the development of seasonal
influenza vaccine was discussed in Chapter 3. An exploratory analysis of a pooling
of four trials showed that post-vaccination HI titres were significantly associated with
the risk of developing clinical influenza. However, we also found out that an absolute
threshold for this COP was not relevant since risks of infection with seasonal influenza
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depended also on uncontrollable and unobserved factors such as exposure to the virus.
In the model developed in Chapter 3 we included season strength as an indicator of the
level of exposure. In Chapter 4 we presented a simulation framework that accounts
for varying exposure levels between countries, through historical data and contacts
behaviours. The analysis methodology we propose in Chapter 6 accounts for exposure
heterogeneity between countries.
Combining simulations and analytical results, we then explored the limit of the current
methodologies for designing phase III efficacy trials (Chapter 4) and analysing the col-
lected data (Chapter 5). To reach this goal, we had to develop a simulation framework
for the generation of phase III clinical trials time-to-infection data. Our methodology
is presented in Chapter 4 and accounts for subjects heterogeneity in fragility and in
contact rates, two possible mechanisms of vaccine protection and strain heterogeneity
in intensity and time course between countries.
In Chapter 4 we showed that small departure from trial hypotheses, especially at the
strains-related level, was associated with large decreases in power to show significant
VE. This results gives us a better understanding of the potential causes for the lack
of significant efficacy observed in recent trials and also in the discordances observed
in other cases. In Chapter 5, we investigated the robustness of the classical regres-
sion model used to analyse seasonal influenza VE trial data. We showed that in this
specific context, because the AR are particularly small, simple models not accounting
for sources of heterogeneity still gave good estimates and precision for VE. We also
showed that more complex models did not always give better results and, in some
cases, were even not easily applicable due to the characteristics of influenza. So, de-
spite the complexity of the influenza context, analysing VE trial with simple models
seems to be adequate.
Finally, in Chapter 6, we put in question the actual objectives and decision-making
process of phase III trials and proposed a totally new way of approaching the design
and the analysis of those trials. We challenged the use of confidence intervals for mean
VE and we suggested the use of analysis models allowing heterogeneity in VE across
countries and seasons and the derivation of predictive intervals instead of confidence
intervals.
Practical perspectives
While our work is directly related to the conduct of phase III VE trials, we feel that
the issue is more global and, in hindsight, what we have studied here can be integrated
from the very beginning of product development.
First, to develop a pharmaceutical product, the targeted pathology should be character-
ized and the expected impact of the product well defined (Burman et al. 2005; Burman
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and Wiklund 2011). This work and the full development of the product should involve
a team of physicians, pharmacologists, laboratory researchers, epidemiologists and
statisticians among others. In Chapter 2 we tried to define the dynamics of seasonal
influenza and influenza vaccine. Knowledge about any pathology is not static but
instead requires continuous updating to reflect the latest information and evidence.
Second, the intermediate and final objectives to achieve should be clearly defined.
As the product development advances and depending on the state of the market for
the product, objectives should be re-evaluated. Uncertainties and risks about the de-
velopment of the product should be identified as soon as possible. In Chapter 2, we
identified several sources of uncertainties and potential issues with the development
of a seasonal influenza vaccine. Ways to reduce these uncertainties should be inte-
grated into the product development plan. For example, in the case of vaccine against
seasonal influenza, identification and specification of COP should be kept in mind at
all development phases. In Chapter 3, we pooled data from four efficacy trials that
used different seasonal influenza vaccines to gain information about post vaccination
HI titres as a COP. This information will then be re-injected and updated to develop
new vaccines against seasonal influenza. For example, we confirmed that a four-fold
pre-post vaccination titre increase was associated with a two-fold decrease in the risk
of being infected with seasonal influenza for the virus strain A/H3N2. This link should
be confirmed in novel trials and studied for other virus strains. While collecting post-
vaccination blood sample in all phase III trials participants may be costly and/or not
feasible, substantial amount of information may be achieved by combining data from
different pharmaceutical companies.
Uncertainties should also be taken into account in designing the stages of a CT.
O’Hagan et al. (2005) point out that powering of a CT is conventionally done con-
ditionally on an expected fixed treatment effect. Because there is no guarantee that the
true underlying effect will be equal to the assumed value, they state that power does
not quantify the probability of a successful trial. Instead, they recommend the use of
an assurance strategy. They define assurance as "the unconditional probability that the
trial will yield a positive outcome". The simulation methodology presented in Chapter
4 can be seen as an assurance tool. Here, the uncertainty about VE against seasonal
influenza is explored from a mechanistic, epidemiology-inspired model perspective.
By envisaging different scenarios, we can test the robustness of the chosen strategy to
the identified risks. This additional step may be time-consuming but the benefit would
be better probabilities of success of future trials and therefore may eventually decrease
the time-to-licensure.
When designing a life development plan and its trials, an assurance strategy requires
the integration of many factors and extensive information about both the disease and
the product. At the analysis stage however, we recommend a very different strategy,
adopting the simplicity principle: the objective is not to fit the perfect model, matching
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all the characteristics of the data generation process, but to use a statistical model that
gives reliable estimations of the quantity of interest, in this case VE. In Chapter 5 we
showed that analysis regression models omitting sources of heterogeneity gave good
estimates of VE in the specific context of infectious diseases characterized by low AR.
Finally, in order to answer the questions of CT, we firmly believe that uncertainties
should be integrated in the decision-making stage. For a phase III trial, the main ob-
jective should be to show the efficacy of the product in new subjects. In Chapter 6, we
recommended the use of predictive intervals instead of confidence intervals for this
purpose. We showed that confidence intervals gave an incomplete answer to this ob-
jective and that statistically significant mean VE in one trial did not ensure VE in new
countries and seasons. On the opposite, predictive intervals and more particularly tol-
erance intervals provide information about VE in the future. While this methodology
is associated with larger and longer clinical trials, it also provides better insight on the
range of future vaccine efficacies and, as such, provides the patients and physicians
with a more complete knowledge of the product. For phase III trials, the criteria of
success based on predictive intervals should be re-discussed with the health authorities
as they address a different question than the confidence intervals. VE heterogeneity
across countries and seasons should also be assessed after a novel vaccine has been
released to the market and should therefore be included as an objective of phase IV
trials.
Further development
The work started in this thesis was ambitious. While we hope to have opened some
doors towards new VE CT methodology, further work is necessary.
Here, we have only considered the traditional two-arms parallel design. However, in-
novative protocols and designs could be explored. Indeed, in large vaccine efficacy
trials, the amount of information collected on each subject is quite limited. The type
of vaccine administered, prior vaccination history, location (country, center), gender,
age and pre-existing conditions are the usually collected variables. As a result, very
little is known about the subject susceptibility to the vaccine-targeted infection, re-
sulting in important non-explained heterogeneity when modelling the infection risks.
One important unknown quantity is the level of exposure to the infection undergone
by a subject. Ideally, one would like to estimate vaccine efficacy conditionally on
virus exposure, such as in a challenge studies. To reduce uncertainty about the level
of exposure, covariates that could be indicators of contacts (overall) or contacts with
infected people should be collected: jobs, family sizes, use of collective transporta-
tions are examples of such variables. Also, the typical number of daily contacts should
be collected, at least in a subset subjects who would be asked to fill in a contact diary
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(Mossong et al. 2008) for a short period. Finally, clinical trials should include informa-
tion on small clusters of subjects, such as households, school-aged children attending
the same classes, colleagues sharing the same office at work and so on. From the
moment member within a cluster becomes infected, all other cluster members can be
considered as exposed to the virus and would be monitored closely. Vaccine efficacy
could thus be estimated conditionally on exposure. Such trials, including household
contact information, have been conducted in order to study antiviral drug efficacy
(Halloran et al. 2007).
To control for subject exogenous characteristics, CT should be run over several sea-
sons through a cross-over design. Subjects would be vaccinated during one season
and not the other, and as such would be their own control. This design has been used,
for example, in the context of other vaccines studies (Park et al. 2004). However, this
design would be impossible to apply in a population in whom vaccination is recom-
mended as the standard of care by the health authorities, such as the elderly in the case
of influenza and pneumococcal vaccines.. Also, the effect of vaccine history is contro-
versial in the seasonal influenza context (Hoskins et al. 1979; Beyer et al. 1999) and
pharmaceutical companies usually prefer to test their vaccines in a naive population
(Keitel et al. 1997), i.e. subjects who did not receive the vaccine previously. Brown
and Lilford (2006) propose a design called "stepped wedge trial" in which a treatment
is rolled-out sequentially to the trial participants over a number of time periods. In
this design, subjects who have received the experimental treatment do not go back to
the comparator. In all cases, careful care should be taken to control for the differences
in levels of exposure between seasons.
In our work, we have considered laboratory-confirmed influenza infection as the only
endpoint. However, this endpoint might be ameliorated. For example, the severity
of the disease should be considered. Indeed, a significant reduction of the severity of
the disease through vaccination might be an appealing vaccine benefit since it would
mean lower burden for the sick person but might also lead to reduction of the conta-
giousness and thus indirect protection of the community. Samples obtained from trial
participants are only sent for analysis when subjects experienced clinical manifesta-
tions of influenza. However, it is likely that some subjects would be infected without
experiencing any symptoms. Nichol (2006) proposes a discussion about the impact of
heterogeneity in case-definitions for influenza in the interpretation of trial results.
Finally, while we have suggested to extend phase III seasonal influenza VE trials over
several seasons, we have not explored the monitoring strategies for interim analyses
and decision-making methodologies that could be applied to this design. Among other
possibilities, stochastic curtailment (Jennison and Turnbull 2010) seems an appealing
solution. In this methodology, conditional power is used as a basis for stopping the
trial. The trial is terminated, for efficacy or lack of efficacy, as soon as a particular
decision is highly likely given the current data (Davis and Hardy 1994). Lin et al.
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(1999) provide a general theory for applying stochastic curtailment to survival data.
Harvey and Kagerer (2005) and Dimitrienko and Wang (2006) provide solutions for
the monitoring of clinical trials through Bayesian statistics. However, to gain infor-
mation about season heterogeneity, we do not recommend to stop trials too early. The
situation where there appears to be a lack of vaccine efficacy should also be discussed
extensively as lack of efficacy in some clusters might be the results of VE heterogene-
ity.
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